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ABSTRACT 
 
The objective of this research topic is to show QbD and PAT tools such as 
multivariate analysis can perform “Continued Process Verification by using a Real-
Time Multivariate Process Monitoring (RT-MSPM) system.   There are not one but 
many challenges The pharmaceutical and bio-pharmaceutical manufacturers are 
facing multiple challenges such as changing regulatory requirements, healthcare 
reforms, economic pressure and availability of advance manufacturing technology to 
make better quality products at reduced costs. 
 
Due to the recent technological developments, significant opportunities exist for 
improving pharmaceutical development, manufacturing and quality assurance through 
innovation in product and process development, process analysis, and process 
controls.    The latest FDA guidelines such as QbD, PAT and the 2011 process 
validation have opened the doors for “Real-Time Process Monitoring” concepts for 
“Continued Process Verification”.   
 
The regulatory agencies have taken the initiative by providing guidelines in last ten 
years such as,  Pharmaceutical cGMPs for the 21st Century - A Risk Based Approach, 
Final Report in September 2004 [1], Guidance for Industry: PAT - A Framework for 
Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance [2], 
Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good 
Manufacturing Practice Regulations [3],  Internal Commerce for Harmonization 
(ICH) - guidelines [4, 5, 6, and 7], QbD, a perspective from the “Office of 
Biotechnology Products” (OBP) [8] and lastly, Guidance for Industry Process 
Validation General Principles and practices utilizing three stages during Process 
Validation [9]. 
 
The objective of agency is to ensure that the most up-to-date concepts of risk 
management and quality systems approaches are incorporated into the manufacturing. 
 
  
The application of multivariate statistical models for process monitoring can provide 
information on the challenges that are routinely encountered by drug manufacturers 
and process can be monitored in real-time to achieve continued process verification 
(CPV). The outcome of the study is intended to become a benchmark for biological 
manufacturers who are interested in applying the “PAT tools” for existing legacy 
products or any new manufacturing process to address challenges [10, 11] such as 
raw material variation and control of process variability, identifying and monitoring 
of relevant process parameters in the operating space, RT-MSPM with early fault 
detection and diagnosis of process upsets and trends.  
 
PCA (Principal Component Analysis (PCA) and PLS (Projection to Latent Structure 
(PLS) are the two popular techniques are used to create the multivariate (MV) 
models.   MV statistical models for process monitoring are used in this study to 
address the challenges in biologics manufacturing process such as raw material 
variation and control of process variability, identification and monitoring of relevant 
process parameters in the operating space and RT-MSPM for Early Detection and 
Diagnosis of Process Upsets and Trends. 
The implementation of RT-MSPM assists in meeting the latest process validation 
guidance requirement to achieve continued process verification (CPV) by monitoring 
each and every batch in real time.  With the use of RT-MSPM tool, every run can be 
considered as a process validation run.  If the process is monitored in real time then 
the sampling frequency can be reduced significantly, which can result in tremendous 
cost saving. 
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PREFACE 
 
 
This thesis is prepared according to the manuscript format. The manuscripts are included. 
 
MANUSCRIPT 1:  APPLYING QBD AND PAT IN COMMERCIAL BIOLOGICS 
MANUFACTURING, VALIDATION OF PROCESS MONITORING TOOL AND BENEFIT 
EVALUATION 
 
MANUSCRIPT 2:  USE OF MULTIVARIATE STATISTICAL PROCESS MONITORING TO 
ACHIEVE CONTINUED PROCESS VERIFICATION  
 
The first manuscript will be submitted for publication in Journal of Pharmaceutical 
Innovation.  The second manuscript will be submitted for publication in PDA’s Journal of 
Pharmaceutical Sciences and Technology. 
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BACKGROUND 
 
Regulatory Guidance Related to PAT (Process Analytical Technology) and QbD (Quality 
by Design):  
 
PAT is a system for designing, analyzing, and controlling manufacturing through timely 
measurements of critical quality and performance attributes of raw and in-process 
materials and processes with the goal of ensuring final product quality.  
The term analytical in PAT is viewed broadly and includes chemical, physical, microbial, 
mathematical, and risk analysis conducted in an integrated manner. The goal of PAT is to 
enhance understanding and control the manufacturing process. Quality cannot be tested 
into products; it should be built-in or should be by design. Consequently, the tools and 
principles described in this guidance should be used for gaining process understanding 
and can also be used to meet the regulatory requirements for validating and controlling 
the manufacturing process [2]. 
Using the approach of building quality into products, PAT guidance highlights the 
necessity for process understanding and opportunities for improving manufacturing 
efficiencies through innovation and enhanced scientific communication between 
manufacturers and the agency. Increased emphasis on building quality into products 
allows more focus to be placed on relevant multi-factorial relationships amongst material, 
manufacturing process, environmental variables, and their effects on quality. This 
enhanced focus provides a basis for identifying and understanding relationships among 
various critical formulation and process factors and for developing effective risk 
mitigation strategies (e.g., product specifications, process controls, training, etc.). The 
data and information to help understand these relationships can be leveraged through pre-
formulation programs, development and scale-up studies, as well as from improved 
analysis of manufacturing data collected over the life of a product.  
A desired goal of the PAT framework is to design and develop well understood processes 
that will consistently ensure a predefined quality at the end of the manufacturing process. 
Such procedures would be consistent with the basic tenet of QbD and could reduce risks 
to quality and regulatory concerns while improving efficiency. Gains in quality, safety, 
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and/or efficiency will vary depending on the process and the product, and are likely to 
come from reducing production cycle times by using on-line, in-line, and/or at-line 
measurements and controls ; preventing rejects, scrap, and re-processing ; real time 
release; increasing automation to improve operator safety and reduce human errors ; 
improving energy and material use and increasing capacity; facilitating continuous 
processing to improve efficiency and manage variability.  
 
This guidance facilitates innovation in development, manufacturing and quality assurance 
by focusing on process understanding. These concepts are applicable to all manufacturing 
situations.  
 
Process Understanding [2, 8] 
 
A process is generally considered well understood, when variability from batch to batch 
is explained, a good run from bad run is predicted, and all the factors that can alter 
quality, are accounted for and are understood.  
 
A focus on process understanding can reduce the burden for validating systems by 
providing more options for justifying and qualifying systems intended to monitor and 
control biological, physical, and/or chemical attributes of materials and processes. 
Structured product and process development on a small scale, using experimental design 
and on-line or in-line process analyzers to collect data in real time, can provide increased 
insight and understanding for process development, optimization, scale-up, technology 
transfer, and control. Process understanding then continues in the production phase when 
other variables (e.g., environmental and supplier changes) may possibly be encountered. 
Therefore, continuous learning over the life cycle of a product is important.  
 
Real-time multivariate statistical process monitoring provides a means to proactively 
monitor this overall process variability. It build the necessary foundation towards 
predictive monitoring which is aligned with the regulatory agency expectation on risk 
management and continual process improvement post-commercialization [11,12]. 
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Principles of PAT [12] 
Pharmaceutical manufacturing processes often consist of a series of unit operations, each 
intended to modulate certain properties of the materials being processed. To ensure 
acceptable and reproducible modulation, consideration should be given to the quality 
attributes of incoming materials and their process-ability for each unit operation.  
 
During the last three decades, significant progress has been made in developing analytical 
methods for chemical attributes (e.g., identity and purity). However, certain physical and 
mechanical attributes of pharmaceutical ingredients are not necessarily well understood. 
Consequently, the inherent, undetected variability of raw materials may be manifested in 
the final product.  
 
Establishing effective processes for managing physical attributes of raw and in-process 
materials requires a fundamental understanding of attributes that are critical to product 
quality. Such attributes may pose a significant challenge because of their complexities 
and difficulties related to collecting representative samples. Since the Formulation design 
strategies are not generalized, the quality of these formulations can be evaluated only by 
testing samples of in-process materials and end products.  
 
Currently, these tests are performed off line after preparing collected samples for the 
analysis. Different tests are needed because they only address one attribute of the active 
ingredient following sample preparation (e.g., chemical separation to isolate it from other 
components). During sample preparation, other valuable information pertaining to the 
formulation matrix is often lost.  
 
Several new technologies are now available that can acquire information on multiple 
attributes with minimal or no sample preparation. These technologies provide an 
opportunity to assess multiple attributes, often nondestructively. 
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Appropriate use of PAT tools and principles (described below) can provide relevant 
information relating to physical, chemical, and biological attributes. The process 
understanding gained from this information will enable process control and optimization, 
address the limitation of the time-defined end points discussed above, and improve 
efficiency. 
  
Process Analytical Technology Tools [2] 
 
There are many new tools available that enable scientific, risk-managed pharmaceutical 
development, manufacture, and quality assurance. These tools, when used within a 
system can provide effective and efficient means for acquiring information to facilitate 
process understanding, develop risk-mitigation strategies, achieve continuous 
improvement, and share information and knowledge.  
 
Producing a product consistently rests on four key areas of technology:  multivariate data 
analysis, process analyzers, process automation/control and knowledge management.  
 
When all of these ingredients are added to the mix, powerful solutions can be realized. 
Typically, collecting information from sensor and instruments is not complicated. Servers 
are bursting with data about processes. However, getting the process engineer the 
information he or she needs requires intensive IT involvement. 
 
Even more importantly is getting access to this data in real time to make decisions about 
quality. 
 
In the PAT framework, these tools can be categorized as: 
 
I. Multivariate (more than one variable) data acquisition and analysis 
II. Modern process analyzers or process analytical chemistry tools 
III. Process and endpoint monitoring and control tools 
IV. Continuous improvement and knowledge management tools 
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An appropriate combination of some, or all, of these tools may be applicable to a single-
unit operation, or to an entire manufacturing process and its quality assurance.  
 
Multivariate (more than one variable) data acquisition and analysis: 
From a physical, chemical, or biological perspective, pharmaceutical products and 
processes are complex, multi-factorial systems. There are many development strategies 
that can be used to identify optimal formulations and processes. The knowledge acquired 
in these development programs is the foundation for product and process design.  
This knowledge base can help to support and justify flexible regulatory paths for 
innovation in manufacturing and post approval changes. A knowledge base can be a 
benefit when it consists of scientific understanding of the relevant multi-factorial 
relationships (e.g., between formulation, process, and quality attributes), as well as a 
means to evaluate the applicability of this knowledge in different scenarios (i.e., 
generalization). This benefit can be achieved through the use of multivariate 
mathematical approaches, such as statistical design of experiments, response surface 
methodologies, process simulation, and pattern recognition tools, in conjunction with 
knowledge management systems. The applicability and reliability of knowledge in the 
form of mathematical relationships and models can be assessed by statistical evaluation 
of model predictions.  
Methodological experiments based on statistical principles of orthogonality, reference 
distribution, and randomization; provide effective means for identifying and studying the 
effect and interaction of product and process variables. Traditional one-factor-at-a-time 
experiments do not address interactions among product and process variables.  
When used appropriately, these tools enable the identification and evaluation of product 
and process variables that may be critical to product quality and performance. The tools 
may also identify potential failure modes and mechanisms and quantify their effects on 
product quality.  
Modern process analyzers or process analytical chemistry tools:   
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Process analysis has advanced significantly during the past several decades, due to an 
increasing appreciation for the value of collecting process data. Industrial drivers of 
productivity, quality, and environmental impact have supported major advancements in 
this area. Available tools have evolved from those that predominantly take univariate 
process measurements, such as pH, temperature, and pressure, to those that measure 
biological, chemical, and physical attributes. Indeed some process analyzers provide 
nondestructive measurements that contain information related to biological, physical, and 
chemical attributes of the materials being processed. These measurements can be At-line: 
Measurement, On-line Measurement and In-line Measurement.   
Process analyzers typically generate large volumes of data. Certain data is likely to be 
relevant for routine quality assurance and regulatory decisions. In a PAT environment, 
batch records should include scientific and procedural information indicative of high 
process quality and product conformance. For example, batch records could include a 
series of charts depicting acceptance ranges, confidence intervals, and distribution plots 
(inter- and intra-batch) showing measurement results. Ease of secure access to these data 
is important for real time manufacturing control and quality assurance. Installed 
information technology systems should accommodate such functions.  
Measurements collected from these process analyzers need not be absolute values of the 
attribute of interest. The ability to measure relative differences in materials before (e.g., 
within a lot, lot-to-lot, different suppliers) and during processing will provide useful 
information for process control. A flexible process may be designed to manage variability 
of the materials being processed. Such an approach can be established and justified when 
differences in quality attributes and other process information are used to control (e.g., 
feed-forward and/or feed-back) the process.  
The advances in process analyzers made the real time control and quality assurance 
during manufacturing feasible. However, multivariate methodologies are often necessary 
to extract critical process knowledge for real time control and quality assurance.  
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Comprehensive statistical and risk analyses of the process are generally necessary to 
assess the reliability of predictive mathematical relationships. Based on the estimated 
risk, a simple correlation function may need further support or justification, such as a 
mechanistic explanation of causal links among the process, material measurements, and 
target quality specifications. For certain applications, sensor-based measurements can 
provide a useful process signature that may be related to the underlying process steps or 
transformations. Based on the level of process understanding, these signatures may also 
be useful for process monitoring, control, and end point determination when these 
patterns or signatures relate to product and process quality.  
Design and construction of the process equipment, the analyzer, and their interfaces are 
critical to ensure that collected data are relevant and representative of process and 
product attributes. Robust design, reliability, and ease of operation are important 
considerations.  
Installation of process analyzers on existing process equipment in production should be 
done after risk analysis to ensure this installation does not adversely affect process or 
product quality.  
A review of current standard practices (e.g., ASTM International) for process analyzers 
can provide useful information and facilitate discussions with the Agency. A few 
examples of such standards are listed in the bibliography section. Additionally, standards 
forthcoming from the ASTM Technical Committee E55 may provide complimentary 
information for implementing the PAT Framework. We recommend that manufacturers 
developing a PAT process consider a scientific, risk-based approach relevant to the 
intended use of an analyzer for a specific process and its utility for understanding and 
controlling the process.  
Process and endpoint monitoring and control tools: 
It is important to emphasize that a strong link between product design and process 
development is essential to ensure effective control of all critical quality attributes. 
Process monitoring and control strategies are intended to monitor the state of a process 
and actively manipulate it to maintain a desired state. Strategies should accommodate the 
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attributes of input materials, the ability and reliability of process analyzers to measure 
critical attributes, and the achievement of process end points to ensure consistent quality 
materials and the final product.  
The design and optimization of drug formulations and manufacturing processes within 
the PAT framework can include steps such as identifying critical attributes, measurement 
of the critical attributes, design process control to monitor and maintain these attributes 
within the operating space.   
Within the PAT framework, a process end point is not a fixed time; rather it is the 
achievement of the desired material attribute. This, however, does not mean that process 
time is not considered. A range of acceptable process times (process window) is likely to 
be achieved during the manufacturing phase and should be evaluated, and considerations 
for addressing significant deviations from acceptable process times should be developed.  
Where PAT spans the entire manufacturing process, the fraction of in-process materials 
and final product evaluated during production could be substantially greater than what is 
currently achieved using laboratory testing. Thus, an opportunity to use more rigorous 
statistical principles for a quality decision is provided. Rigorous statistical principles 
should be used for defining acceptance criteria for end point attributes that consider 
measurement and sampling strategies. Multivariate Statistical Process Control can be 
feasible and valuable to realizing the full benefit of real time measurements. Quality 
decisions should be based on process understanding and the prediction and control of 
relevant process/product attributes. This is one way to be consistent with relevant CGMP 
requirements, as such control procedures that validate the performance of the 
manufacturing process (21 CFR 211.110(a)).  
Systems that promote greater product and process understanding can provide a high 
assurance of quality on every batch and provide alternative, effective mechanisms to 
demonstrate validation (per 21 CFR 211.100(a), i.e., production and process controls are 
designed to ensure quality). In a PAT framework, validation can be demonstrated through 
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continuous quality assurance where a process is continually monitored, evaluated, and 
adjusted using validated in-process measurements, tests, controls, and process end points.  
Risk-based approaches are suggested for validating PAT software systems. The 
recommendations provided by other FDA guidance, such as General Principles of 
Software Validation [17] should be considered. Other useful information can be obtained 
from consensus standards, such as ASTM.  
Continuous improvement and knowledge management tools:  
Continuous learning through data collection and analysis over the life cycle of a product 
is important. These data can contribute to justifying proposals for post approval changes. 
Approaches and information technology systems that support knowledge acquisition 
from such databases are valuable for the manufacturers and can also facilitate scientific 
communication with the Agency.  
Opportunities need to be identified to improve the usefulness of available relevant 
product and process knowledge during regulatory decision making. A knowledge base 
can be of most benefit when it consists of scientific understanding of the relevant multi-
factorial relationships (e.g., between formulation, process, and quality attributes) as well 
as a means to evaluate the applicability of this knowledge in different scenarios (i.e., 
generalization). Today's information technology infrastructure makes the development 
and maintenance of this knowledge base practical.  
Process Validation Guidance   
A typical biologics manufacturing process starts with inoculation phase and end up into 
final product which is distributed to patients as shown in Figure 1 [25]. This process 
involves several upstream unit operations such as series of cell culture bioreactors, 
centrifuges, filtration steps and downstream unit operations such as chromatography, 
ultra-filtration and diafiltration (UF/DF), viral inactivation, etc.  
 
Traditional Process Validation Approach: Per 21 CFR Parts 210 and 211, and of the 
Good Manufacturing Practice Regulations for Medical Devices, 21 CFR Part 820[15], 
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every pharmaceutical or biologics manufacturing organization has to go through rigorous 
testing and qualification phase before they seek  approval for  large scale manufacturing 
of drug substance or drug product.  The term “qualification” and “validation” are separate 
terms but are interchangeably used in the industry [16].  The FDA’s definition of 
validation is “Establishing documented evidence that a process or system, when operated 
within established parameters can perform effectively and reproducibly to produce a 
medicinal product, that meets its pre-determined specifications and quality attributes 
[17]”.  
 
In other words, each and every piece of equipment used in the manufacturing facility 
needs to undergo Installation, Operational and Performance Qualification processes to 
meet the guidance. The automated and computerized systems needs to go through 
“Software Validation [16] and Part 11 Compliance for electronics records and electronic 
signature validation [18] to ensure that the data inputs and outputs of these systems are 
secured and trust worthy just like paper records. It ensures that all the critical equipment 
is installed correctly; operate with the operating ranges and performs within the 
acceptable criteria. 
 
Upon completion of above mentioned validation process, the process validation is 
performed. Process validation is a federal requirement therefore; it is applicable to all the 
manufacture of pharmaceuticals and medical devices. Per “Guideline on general 
principles of process validation, May 1987”, manufacturing processes needed to be 
validated. Assurance of product quality was derived from careful attention to a number of 
factors including selection of quality parts and materials, adequate product and process 
design, control of the process, and in-process and end-product testing [17]. 
 
As stated in old process validation guidance, the manufacturers needed to perform 
confirmation runs a.k.a process validation runs to prove that the process is capable of 
effectively meeting the key and critical process parameter acceptance criteria. The key 
and critical operating parameters were within operating ranges and the process was able 
to generate the product in a controlled manner. The analytical assays tested the incoming 
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raw materials; in process material and finished product material to ensure that that they 
meet the specifications.  The guidelines suggested establishing robust test protocols to 
specify “A sufficient number of replicate process runs to demonstrate reproducibility and 
provide an accurate measure of variability among successive runs [17]”. It did not exactly 
specify how many runs. The manufacturing industry started performing three process 
validation runs and soon it became a norm. The standard industry practice became three 
consecutive process validation runs. Upon completion of this torturous, expensive and 
time consuming process FDA inspected the facilities gave approvals to manufacture the 
drug substances or drug products. The process was never validated after that throughout 
its lifecycle. 
 
FDA’s lifecycle Approach for Process validation: In 2011 FDA came up with new 
process validation guidance. This guidance is aligned with existing FDA guidance, 
including the FDA/International Conference on Harmonization (ICH) guidance for 
industry, Q8 - Pharmaceutical Development [4], Q9- Quality Risk Management [5], Q10 
- Pharmaceutical Quality System [6] and Q11- Development and manufacture of drug 
substances [7].  Although; this guidance does not repeat the concepts and principles 
explained in other guidance’s, FDA encourages the use of modern pharmaceutical 
development concepts, quality risk management, and quality systems at all stages of the 
manufacturing process lifecycle [9].  
Per this new guidance, manufacturers are required to adopt the lifecycle approach by 
performing the process validation activities in three stages [9] after completing the 
equipment and facility qualification.  
The three stages in the lifecycle approach outlines the development phase where the 
product knowledge and process understanding is gained to establish the operating space. 
The stage 1 is linked to process qualification stage for process validation. Utilizing the 
stage 1 and 2, the new expectation is to perform the continued process verification (CPV) 
to ensure that process remains in the control and consistently make the quality product.  
Three stages of process validation are outlined below:  
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I. In Stage 1, process design, the commercial process is defined based on knowledge 
gained through development and scale-up activities.  
II. In Stage 2, process qualification, the process design is evaluated and assessed to 
determine if the process is capable of reproducible commercial manufacturing.  
III. In Stage 3, continued process verification, ongoing assurance is gained during 
routine production that the process remains in a state of control.  
Pre-Requisites of PAT Implementation [2]: 
In order to get PAT on a more practical and operational level, we can list a number of 
prerequisites: 
  
Infrastructure: Automated data acquisition systems, databases, networks, and 
synchronization procedures must be in place. The greatest hurdle involved in almost any 
analysis is generation, integration and organization of data. This is particularly true for 
the pharmaceutical industry where data are often stored in vast warehouses but rarely, if 
ever, retrieved and used. Past regulatory environments did not provide incentives for 
analysis of manufacturing processes because implementing improvements required re-
validation and the current condition of pharmaceutical data infrastructures reflects this. 
As a result large efforts are required to assemble meaningful datasets. This challenge is 
further complicated given that laboratory and production data are scattered in various 
disconnected databases. Examples of these databases include Laboratory Information 
Management Systems (LIMS), Manufacturing Execution Systems (MES), Enterprise 
Resource Planning systems (ERP) as well as Supervisory Control and Data Acquisition 
systems (SCADA) and process historian databases. Product quality is influenced by all 
stages of production including variability of the raw materials. Developing process 
understanding of a finished product can only be realized through uncovering the 
cumulative influence of all processing steps and their interactions. Integrating, 
synchronizing and aligning data from all relevant sources is therefore a pre-requisite 
before analysis can begin. 
 
Multivariate characterization:  Adequate and informative data must be measured on all 
steps and ingredients of the process. 
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Multivariate evaluation of all data:  All data should be analyzed together. The data 
analysis should not focus on variable selection, should not be univariate in nature, and 
should not involve methods with many adjustable parameters which are prone to over fit. 
The data analysis phase should entail simple, transparent, informative, and reversible 
projection models. 
 
Data and information integration and communication:  All data flows and data bases 
should be integrated onto one common platform. This facilitates use of data, visualization 
of data, and communication of results. 
 
Design of Experiment (DOE):  A suitable use of DOE combined with some of the steps 
above can augment the analysis and help to ensure that critical system parameters are 
varied together in a simultaneous to get the optimum information from the experiments. 
 
Strategy for Implementation of PAT [2]  
The Agency understands that to enable successful implementation of PAT, flexibility, 
coordination, and communication with manufacturers is critical. The Agency believes 
that current regulations are sufficiently broad to accommodate these strategies. 
Regulations can effectively support innovation when clear, effective, and meaningful 
communication exists between the Agency and industry, for example, in the form of 
meetings or informal communications.  
 
The first component of the PAT framework described above addresses many of the 
uncertainties with respect to innovation and outlines broad principles for addressing 
anticipated scientific and technical issues. This framework should assist a manufacturer 
in proposing and adopting innovative manufacturing and quality assurance. The Agency 
encourages such proposals and has developed a regulatory strategy to consider such 
proposals.  
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Ideally, PAT principles and tools should be introduced during the development phase. 
The advantage of using these principles and tools during development is to create 
opportunities to improve the mechanistic basis for establishing regulatory specifications. 
Manufacturers are encouraged to use the PAT framework to develop and discuss 
approaches for establishing mechanistic-based regulatory specifications for their 
products. The recommendations provided in this guidance are intended to alleviate 
concerns with approval or inspection when adopting the PAT framework.  
 
In the course of implementing the PAT framework, manufacturers may want to evaluate 
the suitability of a PAT tool on experimental and/or production equipment and processes. 
For example, when evaluating experimental on- or in-line process analyzers during 
production, it is recommended that risk analysis of the impact on product quality be 
conducted before installation. This can be accomplished within the facility's quality 
system without prior notification to the Agency. Data collected using an experimental 
tool should be considered research data. If research is conducted in a production facility, 
it should be under the facility's own quality system.  
 
When using new measurement tools, such as on- or in-line process analyzers, certain data 
trends, intrinsic to a currently acceptable process, may be observed. Manufacturers 
should scientifically evaluate these data to determine how or if such trends affect quality 
and implementation of PAT tools. FDA does not intend to inspect research data collected 
on an existing product for the purpose of evaluating the suitability of an experimental 
process analyzer or other PAT tool. FDA's routine inspection of a firm's manufacturing 
process that incorporates a PAT tool for research purposes will be based on current 
regulatory standards (e.g., test results from currently approved or acceptable regulatory 
methods). Any FDA decision to inspect research data would be based on exceptional 
situations similar to those outlined in Compliance Policy Guide Sec. 130.300.4 Those 
data used to support validation or regulatory submissions will be subject to inspection in 
the usual manner.  
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Challenges of PAT Implementation [2, 8] 
For successful implementation of PAT combination of following areas must be 
considered:  
Organization support:  
One of the most important factors in ensuring the success of process analytical methods is 
strategic organizational support, which can afford to design, implement and maintain the 
PAT systems.  The most PAT systems have significant upfront costs and efforts, they 
require management support. 
 
Implementation of process analytical methods requires the highest level of interaction 
with plant personnel and management. The aspect of ownership and roles and 
responsibilities are handled effectively as long there is continuity in management support.  
 
The development of PAT applications by central groups and subsequent transfer of 
ownership to the plant require the highest level of interaction with plant personnel and 
technology transfer teams. It is critical to success that the interests of central 
organizations and sites are aligned to effectively develop and support the process 
analytical systems, particularly those with relatively high complexity.   
 
Necessary roles in PAT implementation can be filled by personnel from different 
departments:  
 
Management: Provides overall project management, business support and expertise as 
well as strategic oversight 
 
Procurement: Works with vendors to facilitate and coordinate purchase of equipment 
 
Site/Plant Operations: Contributes technical know-how as well as process/manufacturing 
logistics 
 
Process Analytics: Contributes analytical knowledge, analyzer technology development, 
analyzer engineering, implementation support and training 
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Automation and control: Handles efforts in the area of process control and automation of 
process equipment 
 
Maintenance: Responsible for care and feeding of process analytical equipment 
 
Vendor: Provide products and services for PA implementation 
 
Quality: Potential oversight of data and product quality 
 
Regulatory expertise: Necessary for regulatory compliance and strategic partnerships 
with regulatory agencies.  
 
Profile of a process analytical scientist/engineer: For successful implementation of PAT 
project, process analytical personnel should have combination of competencies such as 
technical, interpersonal effectiveness, initiative, business focus, innovative, learning, and 
leadership skills.   
 
Industrial Application of PAT tools: Multivariate Data Analysis (MVDA): 
Due to the recent advancement in the computer technology, we have the capability to 
collect larger amounts of data. This trend will continue to accelerate in the next decades 
as the technological developments continues. Multivariate data analysis (MVDA) is 
becoming increasingly popular because the on-going data collection tends to overload our 
computers and data-bases with tons of data. It is therefore necessary to work on bigger 
samples if full advantage is to be taken of all accessible information. It is also necessary 
to derive as much information as possible from the diversity of the data, rather than 
restricting attention to subsets of it. The use of multivariate data analysis techniques 
provides this opportunity and it can be used to reveal the information otherwise 
impossible to know. By using MVDA we can extract much more information than 
univariate data analysis techniques for the selected variables and observations. This data 
then needs to be analyzed so that meaningful information can be extracted from it. 
MVDA methods are being used in pharmaceutical and biotechnology industries in 
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several areas [12] such as 1) Process monitoring, and early fault detection and 
classification; 2) Process Analytical technology tool; 3) Quality control analysis; 4) Data 
mining and integration; 5) Structure activity relationship; 6) Multivariate 
characterization; 7) Multivariate calibration; and 8) Multivariate characterization and 
discrimination analysis. 
In the biological manufacturing process, tremendous amount of data is generated from 
various sensors during each phase for the respective unit operation. If the manufacturing 
operation is comprised of the high tech data collection sensors, then the amount of data 
can be generated for each phase from few seconds interval to several days interval. The 
in- process test results helps to measure and ensure that the process is running under 
control. This data is stored on the computer and server databases.  
The use of various multivariate analysis techniques such as Principal Component analysis 
(PCA) and Projection to Latent Structures (PLS) modeling can give a meaning to this 
data. ‘The masses of process data can provide easy to grasp graphical information about 
the state of the process, and relations between important sets of process variables. These 
multivariate methods make efficient use of all pertinent data, with little loss of 
information’. [19]  
In order to perform MVDA, it is important to understand the variability, complexity of 
the data and the type of data being analyzed. The MVDA is well suited to deal with 
variability in the complex data, thereby reducing the risk of incorrect inferences. 
However; all the data points are needed. One should not disregard the data because the 
variables are often collinear, either partially or completely. If part of the data is ignored 
then there is a substantial risk of overlooking the important information. 
 
In MVDA, most common and widely-used methods are PCA and PLS. These methods 
present the modeling results graphically and the observations and variables are easily 
available for diagnostics and interpretation. PCA and PLS methods are mainly popular 
because they can deal with the problems related to dimensionality, co-linearity, noise and 
missing data. These methods offer a number of diagnostic tools, which facilitate the 
identification of assignable causes.    
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PCA and PLS can be used to address three main types of data issues such as overview of 
data, classification & discrimination and regression modeling. 
 
Principal Components Analysis (PCA) [14, 20, 39]: 
The PCA method was first introduced by Pearson in 1901. In 1933, Harold Hotelling 
formulated the PCA theory. But, 1980 onwards, due to development of personal 
computers, application of PCA exploded [20].    
 
PCA is a way of identifying patterns in data, and expressing the data in such a way as to 
highlight their similarities and differences. The main advantage of PCA is that once you 
have found these patterns in the data, and you compress the data, i.e. by reducing the 
number of dimensions, without much loss of information [21]. Statistically, PCA finds a 
new lines or planes in the multi-dimensional space that approximate the data as well as 
possible in the least square sense. The goal of PCA is to reduce the number of variables 
of interest into a smaller set of components. First principal component (1
st
 PC) explains 
maximum variation and subsequent PC’s explain remaining variation in a descending 
order [12].   
 
PCA method is useful for over viewing a data matrix X, because it is able to explore 
relationships both among variables and observations. PCA provides the understanding of 
the relationships between variables which contribute similar information to the PCA 
model and which variables provide unique information about the observations.   
 
Principal Components Analysis have several objectives [22] such as dimensionality 
reduction; determining of linear combinations of variables;   choosing of the most useful 
variables;  visualization of multidimensional data; identification of underlying variables; 
identification of groups of objects or outliers.  
The tasks required of the analyst to carry these out are as follows:  
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Dimensionality Reduction: 
In case of a table of dimensions N x M, each of the N rows or observations can be 
regarded as an M-dimensional vector or variables. Finding a set of M’ < M principal axes 
allows the objects to be adequately characterized on a smaller number of (artificial) 
variables. This is advantageous as a prelude to further analysis as the M – M’ dimensions 
may often be ignored as constituting noise; and, secondly, for storage economy 
(sufficient information from the initial table is now represented in a table with M’ < M 
columns). Reduction of dimensionality is practicable if the first M’ new axes account for 
approximately 75 % or more of the variance. There is no set threshold, the analyst must 
judge. The cumulative percentage of variance explained by the principal axes is consulted 
in order to make this choice.  
 
The determining of linear combinations of variables: 
The data matrix X is projected into multidimensional space. PCA method provides the 
understanding of the relationships between variables. This relationship is transformed 
into a covariance matrix.  The eigenvalues and eigenvectors are the properties of matrix. 
The relationship between the variables, their length and the direction of PC vectors is 
explained by eigenvalues and eigenvectors. The eigenvector are found in square matrix, 
its direction is not affected by scaling and they are orthogonal to each other. The 
eigenvalues are closely related to eigenvectors because they always come in pairs. It is 
important in PCA that each eigenvector to be of unit length [21] that means the variance 
of the eigenvector is one.  If the eigenvalue is zero, the variance of projections on the 
associated eigenvector is zero. Hence the eigenvector is reduced to a point. If this point is 
additionally the origin (i.e. the data is centered), then this allows linear combinations 
between the variables to be found. In fact, we can go a good deal further: by analyzing 
second-order variables, defined from the given variables, quadratic dependencies can be 
straightforwardly sought. This means, for example, that in analyzing three variables, y1, 
y2, and y3, we would also input the variables y12, y22, y32, y1y2, y1y3, and y2y3. If the 
linear combination y1 = c1 y22 + c2 y1y2 exists, then we would find it. Similarly we 
could feed in the logarithms or other functions of variables.  
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Feature selection: the choosing of the most useful variables: 
In feature selection we want to simplify the task of characterizing each object by a set of 
attributes. Linear combinations among attributes must be found; highly correlated 
attributes (i.e., closely located attributes in the new space) allow some attributes to be 
removed from consideration; and the proximity of attributes to the new axes indicate the 
more relevant and important attributes. As stated earlier, PCA method calculates the 
eigenvectors and eigenvalues from the relationship matrix. The eigenvector with the 
highest eigenvalue is the principal component of the data set. In general, once 
eigenvectors are found from the covariance matrix, the next step is to order them by 
eigenvalue, highest to lowest. This gives you the components in order of significance 
[21]. This step assists in in choosing the most useful variables. 
 
Visualization of multidimensional data: 
In order to provide a convenient representation of multidimensional data, planar plots are 
necessary. An important consideration is the adequacy of the planar representation: the 
percentage variance explained by the pair of axes defining the plane must be looked at 
here.  
 
Identification of underlying variables: 
PCA is often motivated by the search for latent variables. Often it is relatively easy to 
label the highest or second highest components, but it becomes increasingly difficult as 
less relevant axes are examined. The objects with the highest loadings or projections on 
the axes (i.e. those which are placed towards the extremities of the axes) are usually 
worth examining: the axis may be characterisable as a spectrum running from a small 
number of objects with high positive loadings to those with high negative loadings.  
 
Identification of groups of objects or of outliers: 
A visual inspection of a planar plot indicates which objects are grouped together, thus 
indicating that they belong to the same family or result from the same process. 
Anomalous objects can also be detected, and in some cases it might be of interest to redo 
the analysis with these excluded because of the perturbation they introduce.  
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In this process, the principal components are derived as [23]:  
PC1= b11X1+ b21X2+ … + bk1Xk             (Eqn. 1) 
PC2= b12X1+ b22X2+ … + bk2Xk             (Eqn. 2) 
PCf= b1fX1+ b2fX2 + … + bkfXk              (Eqn. 3) 
 
PCA modeling shows the correlation structure of data matrix X, approximating it by a 
matrix product of lower dimension (TP’), called principal components plus a matrix of 
residuals (E). The PCA model is shown by following equation [12]:  
                                               (Eqn. 4) 
where,  
T = Matrix of scores that summarizes the X-variables 
P’ = Matrix of loadings showing the influence of the variables 
E = Matrix of residuals showing the variation in the data which is left out of modeling 
The PCA model as shown in equation (4) can monitor new batch in real time without 
having to estimate the future portion of the new data point. The score for the new batch 
variable is calculated using equation (5). 
Tpred, k = X new, k * W (P’W)
-1                         
(Eqn. 5) 
where,  
W = Weights of the Matrix of scores that summarizes the X-variables 
 
Projections to Latent Structures (PLS) [12, 14, 24, 35, 39]:  
 
The PLS approach was originated in 1975 by Herman Wold. He developed a simple way 
to estimate parameters in the model called NIPALS (Nonlinear Iterative partial least 
squares). These are later called PLS models. In PLS model, P indicates ‘partial’ because 
it is a partial regression since parameter vector (X variable) is considered fixed in the 
estimation. In 1980, the PLS started to interpret as “Projection to Latent Structures”. 
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PLS is a similar technique which also reduces the dimensionality of the input space X, 
however, it does this while finding the best regression fit against a response variable Y.  
PLS method utilizes regression modelling between two data metrices, usually denoted by 
X and Y, with the aim of predicting Y from X for new observations. This is achieved by 
“Linear Multivariate” modelling. In PLS modelling, the aim is to predict complex 
response or output variables (Y) based on the input variables (X). The precision of PLS 
model increases with increasing number of X variables.  
 
In process modelling the PLS method finds the relationship between input (X variables) 
measured on the process at N time points and corresponding values of Y (output 
variables). The PLS model can project and data table as long as there is a similarity 
between observations. 
 
PLS model consists of a structural part, which reflects the relationships between the latent 
variables, and a measurement component, which shows how the latent variables and their 
indicators are related. 
 
PLS starts by calculating case values. For this purpose, the “unobservable variables are 
estimated as exact linear combinations of their empirical indicators”, and PLS treats 
these estimated proxies as perfect substitutes for the latent variables. The weights used to 
determine these case values are estimated so that the resulting case values capture most 
of the variance of the X variables that is useful for predicting the Y variable. This is 
based on the implicit assumption that all measured variance of the variables in the model 
is useful variance that should be explained. Using these weights, it is then possible to 
determine a value for each unobservable variable, simply by calculating a weighted 
average of its indicators. This results in a model in which all unobservable variables are 
approximated by a set of case values and that can, therefore, be estimated by a set of 
simple, first-generation, ordinary least squares regressions.  
The basic idea of PLS is quite straightforward:  
First, the weight relations, to their respective unobservable variables, are estimated.  
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Second, case values for each unobservable variable are calculated, based on a weighted 
average of its indicators, using the weight relations as an input.  
 
Finally, these case values are used in a set of regression equations to determine the 
parameters for the structural relations. 
 
This explanation makes it obvious that the most crucial part of a PLS analysis is the 
estimation of the weight relations. Of course, it would be easier simply to assume equal 
weights for all indicators, but this approach has two disadvantages: 
 
First, there is no theoretical rationale for all indicators to have the same weighting. 
Because it can be assumed that the resulting parameter estimates of the structural model 
depend on the type of weighting used, at least as long as the number of indicators is not 
excessively large, the (exogenous) assumption of equal weights makes the results highly 
arbitrary. Second, such a procedure does not take into account the fact that some 
indicators may be more reliable than others and should, therefore, receive higher weights. 
 
Consequently, PLS uses a more complex, two-step estimation process to determine the 
weights (w): First, it starts with an outside approximation, in which case values for each 
latent variable are estimated, based on a weighted average of their respective indicators. 
The weights used to calculate this aggregation is determined in a manner similar to a 
principal-components analysis for reflective or regression analysis for formative 
indicators. In the next step, the inside approximation, improved case values are 
determined as a weighted average of neighboring latent variables. For this process, there 
are three different weighting schemes available, but one can demonstrate that the choice 
between them has only a minor impact on the final results. Using this second estimate of 
the case values, the weight relations are modified and the process of inside and outside 
approximation starts from the beginning again and is repeated until convergence of the 
case values is achieved. 
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Hence, being a limited information approach PLS has the advantage that it “involves no 
assumptions about the population or scale of measurement” and consequently works 
without distributional assumptions and with nominal, ordinal, and interval scaled 
variables. However, one has to bear in mind that PLS, like any statistical technique, also 
requires certain assumptions to be fulfilled. Beyond those known from the standard 
regression model, the most important assumption is predictor specification. This 
requirement states that the systematic part of the linear regression must be equal to the 
conditional expectation of the dependent variable and can be considered as fulfilled in 
most cases. PLS is quite robust with regard to several inadequacies (e.g., skewness or 
multicollinearity of the indicators, misspecification of the structural model) and that the 
latent variable scores always conform to the true values. 
 
However, there is also another side of the coin, namely, the problem of consistency at 
large. In general, a consistent estimator can be described as “one that converges in 
probability to the value of the parameter being estimated as the sample size increases”. 
However, because the case values for the latent variables in PLS are aggregates of 
manifest variables that involve measurement error, they must be considered as 
inconsistent.  
 
Therefore, “the path coefficients estimated through PLS converge on the parameters of 
the latent-variable model [only] as both the sample size and the number of indicators of 
each latent variable becomes infinite” a problem known under the term consistency at 
large. Hence in all real-life situations, in which both the number of cases in the sample 
and the number of indicators per latent variable will be finite, PLS tends to underestimate 
the correlations between the latent variables and overestimate the loadings. Only when 
the number of cases in the sample and the number of indicators per latent variable 
increase to infinity do the latent variable case values approach the true values and this 
problem disappears. 
 
PLS modeling consists of simultaneous projections of both the X and Y spaces. The 
coordinates of the points on the X and Y dimensions constitutes the elements of the T and 
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U score matrices, P’ and C’ loading matrices and E and F residual matrices as shown in 
equation-4 and 5. The objective here is [12] to well approximate the X and Y spaces and 
to maximize the correlation between X and Y. 
 
                                                         (Eqn. 4) 
 
                                                        (Eqn. 6) 
 
where,  
T and U= Matrix of scores that summarizes the X-variables and Y variables 
P’ and C’ = Matrix of loadings showing the influence of the variables in X and Y matrix 
E & F= Matrix of residuals showing the variation in the data which is left out of 
modeling for X matrix and Y matrix 
 
The batch level model is used to predict the final performance variable using the X 
matrix T scores as shown in equation-5 and equation-6 [12]. Tpred, k and Ypred, k  in the 
following equation calculate the estimated scores and quality / performance attributes at 
time slice ‘k’ in a given batch. 
Tpred, k = X new, k * W (P’W)
-1                         
(Eqn. 5) 
Ypred, k = Tpred, k * C’
                                           
(Eqn. 7) 
 
Pre-Treatment of Data and Scaling Techniques 
Like any other statistical application, PCA require the data to be pre-processed prior to 
using. The variables often have different numerical ranges. A variable with large range 
has a large variance and a variable with small range has small variance. Since PCA is a 
maximum variance projection method, it follows that a variable with large variance is 
more likely to be expressed in the modeling than a low-variance variable. In order to give 
equal weight to all the variables, the data from the variables needs to standardized. This 
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process is called scaling. A combination of scaling techniques can also be used as shown 
in Figure 2 [26]. There are following ways of scaling the data:    
Mean Centering: For PCA to work properly, you have to subtract the mean from each of 
the data dimensions. The mean subtracted is the average across each dimension. This 
produces a data set whose mean is zero. 
Scaling to Unit Variance:  The long variables are shrunk and short variables are stretched, 
so that, all variables are set to equal length. The UV eliminates the differences due to unit 
of measures so that the variable with high values does dominate the model. 
This is achieved by multiplying each variable by 1/Sk where Sk denotes standard 
deviation of each variable.  
Auto scaling: When unit variance scaling is combined with mean centering, it is denoted 
as ‘auto scaling’. 
Pre-Requisites and Challenges of Multivariate Model Creation [12, 27]: 
Handling of missing data:  It is common in process systems that some batches or phases 
within batches having missing data points or a particular phase is not run for various 
operational reasons.  PCA and PLS techniques inherently capable of predicting missing 
data for historical batches that are considered as representing normal operation and are 
highly repeatable therefore using the estimates for the missing data is acceptable [28]. 
  
Removal of the outliers: PCA discovers strong outliers and moderate outliers. Outliers 
are the observations which do not fit the model. Prior to modeling, outliers in the data set 
should also be detected and removed where applicable. The strong outliers pull the PCA 
model to themselves. The moderate outliers are captured by residual plots. Detection and 
elimination of outliers are critical for reliable and robust modeling and monitoring. There 
also are batch level outliers where a batch level score would be grossly different from the 
rest of the batches most likely due to a difference in the operational batch characteristics 
(e.g., different set points) or too many spikes. The outliers can be detected and removed 
via visual inspection; this can also be done via PCA-based modeling. A PCA model can 
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be developed and scores space is inspected for outlying data points or batches. PCA can 
discover strong and moderate outliers. Strong outliers are found in the PC scores plots 
and Hotelling’s T2 plots and moderate outliers are in the residuals (DModX at batch 
level). 
Alignment of Batch Trajectories: Variability in total duration of the batches (such as 
operational condition switches like set points as well as biological variability such as cell 
growth peak maximum) result in unequal and unaligned batch trajectories across batch 
history. Alignment of the trajectories prior to modeling is important to ensure that (as 
much as possible) the variables or scores at any point during one batch correspond to 
those at the same biological or operational state in other batches.  
There are many different techniques available for alignment of batch trajectories such as, 
use of an indicator or maturity variable [27, 29], dynamic time wrapping technique [12] 
and curve registration technique [27] 
The most commonly used technique, is to align the batches based on a “maturity” (also 
known as an indicator) variable. The maturity variable is selected such a way that it 
should be monotonically increasing/decreasing, smooth and it indicates the end of a batch 
or a phase (such as reaction conversion, column volume totalized or simply time 
elapsed). Measurements on other variables are sampled with respect to the equal intervals 
of this variable so that batch trajectories are also aligned and set to equal size for 
modeling purposes. When there is no maturity variable the local batch time is used. 
SIMCA software by default selects $Time maturity variable for PLS model. The value of 
local batch time or maturity predicted by PLS model is suitable for a “maturity index” 
that can be used to indicate how far the batch has evolved [12].    
Unfolding of three dimensional data into two dimensional data [12]: 
 
Using SIMCA software, we can do two levels of batch monitoring; the batch evolution 
level monitoring (BEM) and batch level monitoring (BLM).  
BEM Modelling: 
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The aim of batch evolution level monitoring is to develop a model of the good batches 
and monitor new batches against this model as they evolve to find out if they are evolving 
within the confidence limits. A data generated by a batch processes for a biological 
manufacturing process is arranged in the data blocks as shown in Figure 3a & 3b [30]. 
The batches are depicted as “I”, Variables are depicted as “J” and time points are 
depicted as “K”.  In order to do the observation level modeling, the three way batch data 
table must be unfolded in such a way that the direction of the variable is preserved as 
shown in Figure 3a [30]. The resulting two-way matrix then has “I*J” rows and “K” 
columns. Each row contains data points Xijk from a single batch observation (batch I, 
time K and variable J). If the regression is made against local batch time, the resulting 
PLS scores reflect linear t1, t2, and t3 relationships (assuming a model with three latent 
variables) to local time batch time. A PCA on the on the three way data matrix will show 
how the individual observations relate to each other. 
 
BL Modelling:  
In batch level modelling, all the data from input variable matrix (X) and output variable 
matrix (Y) is available. Therefore, the data from the whole batch is used to create a 
model. The aim of the whole batch model is to verify the new whole batch is a good 
batch or bad batch. A data generated by a batch processes for a biological manufacturing 
process is unfolded in such a way that the direction of the batch is preserved. The 
resulting two-way matrix then has “I” rows and “J*K” columns as shown in Figure (3b). 
The resulting PLS model can be used to classify new batches as good or bad. Another 
important objective of batch level model is to understand how Y (output) variable is 
influenced by the X (input) variables.  
 
Model Diagnostics - Selection of correct number of PC  
Once the model is created, the required number of components is determined by cross 
validation technique. In order to ensure that the model is effective, it is important to have 
optimal balance between the goodness of fit and its predictive ability. The good ness of 
fit is given by the parameter R
2 
(explained variation) and the goodness of prediction is 
given by Q
2 
(predicted variation). Usually, R
2
 and Q
2 
vary differently as the complexity 
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of the model increases. Therefore, selection of number of parameters is based on the 
trade-off between goodness of fit and goodness of prediction as shown in Figure 4 [12].   
 
There is another way of selecting number of components. You can plot eigenvalues of 
each component against the number of components as shown in Figure 5 [31]. The 
eigenvalue of the components represent the variation for those respective components. 
Any component whose eigenvalue is less than 1.0 is in most cases are eliminated because 
it reflects the lowest and negligible variance [23]. 
 
Setting the Control Limits [12]: 
Once the batch evolution level and the models are created, the SIMCA software performs 
the rearrangement of reference model scores to create a new matrix. From this new 
matrix the averages and ± 3 standard deviation confidence limits are calculated. A 
number of multivariate statistical monitoring observation level and batch level plots and 
diagnostics are readily available in SIMCA for monitoring new batches in real-time such 
as; score plot, loading plot, DModX plot, Hotelling’s T2 plot, contribution Plot, 
Coefficient plot, VIP (variable importance in projection plot), and Observed vs. Predicted 
relationship plots. 
 
Score Plots and Loading Plots: These plots are typically used at batch level to generate 
displaying the observations as situated in the multi-dimensional plane. These charts 
reveal the information about the how the variables are grouped, the covariance trend, if 
there are any outliers and similarities between them.  
DModX (Distance to the model X) Plot: It is an estimate of how far from the model 
plane, in the X or Y space, the observation is positioned. DModX is used for process 
deviation detection where events are not necessarily explained by the model. The 
distance to model plot is displayed in normalized units after the last component with the 
default significance level of 0.05.  
The DModX is calculated by using following formula [32]:  
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DModX = (i eik
2 / D.F.)1/2    
            
(Eqn. 8) 
where, 
i eik
2   = Residual variable variation 
D.F. = Degrees of freedom (K-A). Where, K= number of variables and A = number of 
components 
If the DModX is larger than the critical limit then it indicates that the observation is an 
outlier in the X space. 
Hotelling’s T2 Plot: These charts are also used for process deviation detection. They 
detect deviations that are explained by the process model (if DModX is in control) and 
within the overall variability but represent unusually high variation comparing to the 
average process behavior.  
 
The Hotelling's T
2
 for observation i, based on A components is calculated by using 
following formula [12]: 
Ti 
2= Σ ((tia - tavg)
2
 / sta
2
)                    (Eqn. 9)
        
 
where; 
s
2
ta = Variance of ta according to the class model. 
Ti
2
 * (N - A) / A (N - 1) 
Follows a F distribution with A and N-A degrees of freedom. 
N = Number of observations in the workset. 
A = Number of components in the model or the selected number of components. 
Hence if 
Ti
2
 > A (N - 1) / (N - A) * Fcritical (p=0.05) 
then observation i is outside the 95% confidence region of the mode. 
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Contribution plots: 
When the Hotelling's T
2 
and/or DModX plots show a deviation (outlier from the 
confidence limit), indicating that some variable(s) are deviating from the historical 
average behavior without diagnosing which variables are contributing the most. 
Contribution plots are then used to explore into the original variable level and inspect 
which variable(s) are contributing to the inflated statistic [19]. 
 
VIP (Variable Importance in projection Plot): 
The VIP (Variable Importance in Projection) plot summarizes the importance of the 
variables both to explain X matrix and to correlate to Y matrix. The VIP values are 
calculated for each X by summing the squares of the PLS loading weights, weighted by 
the amount of sum of squares explained in each model component. The sum of squares of 
all VIP's is equal to the number of terms in the model. Hence, the average VIP is equal to 
1. VIP-values larger than 1 indicates “important” X-variables, and values lower than 0.5 
indicate “unimportant” X-variables. The interval between 1 and 0.5 is a gray area, where 
the importance level depends on the size of the data set. The VIP plot is sorted from high 
to low, and shows confidence intervals for the VIP values, normally at the 95% level 
[19]. 
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FIGURES LISTED IN BACKGROUND 
 
 
 
 
Figure 1: Typical (Biologics) Manufacturing Process [Source: 25]: The process 
involves several upstream unit operations such as inoculation, series of cell culture 
bioreactors, harvest tanks, filtration tanks, centrifuges and downstream unit operations 
such as multiple chromatography operations, multiple ultra-filtration and diafiltration 
(UF/DF) operations, viral inactivation, final filtration and filling and packaging. 
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Figure 2: Data Scaling Techniques [Source: 26]: After mean –centering and unit variance 
scaling all variables will have equal “length” and mean value zero. 
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Figure 3a: Unfolding three way data matrix [Source: 30] the three way table of 
historical batch process data comprises “I”, J variables and K time points. In batch 
evolution model (BEM), this three-way data table is unfolded by preserving the 
variable direction. This gives a two-way matrix with I*K rows and J columns. 
Each row contains data points Xijk from a single batch evolution. 
 
Figure: 3b, the three way table of historical batch process data comprises “I”, J 
variables and K time points. In batch level model (BLM), this three-way data 
table is unfolded by preserving the batch direction. This gives a two-way matrix 
with I rows and J*K columns. Each row contains data points from one single 
batch. 
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Figure 4: A trade-off between the goodness-of-fit (R
2
) and goodness-of-prediction (Q
2
). 
The vertical axis corresponds to the amount of variation and the horizontal axis 
corresponds to the total number of PCs (A) [Source: 12]. The number of components for 
the model is selected on the basis of optimal balance between fit and predictability. 
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Figure 5: Another way of selecting number of components [Source: 31].  The vertical 
axis corresponds to the eigenvalues and the horizontal axis corresponds to the total 
number of PCs. The eigenvalue of the components represent the variation for those 
respective components. Any component whose eigenvalue is less than 1.0 is in most 
cases are eliminated because it reflects the lowest and negligible variance. 
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DEFINITIONS  
 
Term Definition 
Batch level Model 
[19] 
The MV model used for monitoring the batch finger print 
and predicting the final performance variable 
Batch Evolution 
model [19] 
The MV model used for monitoring the batch evolution 
with respect to a maturity variable in real-time 
Chemometrics [24] A way of analyzing chemical data, in which elements of 
both statistical and chemical thinking are combined. 
Continuous 
Process 
Verification [9] 
An alternative approach to process validation in which 
manufacturing process performance is continuously 
monitored and evaluated. 
Design Space [4] The multidimensional combination and interaction of 
input variables (e.g. Material attributes) and process 
parameters that have been demonstrated to provide 
assurance of quality. Working within the design space is 
not considered as a change. Movement out of the design 
space is considered to be a change and would normally 
initiate a regulatory post approval change process. 
Design space is proposed by the applicant and is subject 
to regulatory assessment and approval. 
DModX Plot [12] The statistic showing the distance of the observation to 
the MV model plane. 
Hotelling’s T2 Plot 
[12] 
The statistic summarizes the selected scores. It is a 
measure of how far away an observation is from the 
center of the MV model 
QbD [8, 10] A strategic approach to drug development, Quality by Design 
requires getting the product, process, Packaging and 
manufacturing “right the first time.” 
Quality [33] Per ISO: "Degree to which a set of inherent characteristic 
fulfills requirements" 
Loading Plot [12] It is a summary of variables for observations (batches). It 
is a means to interpret the patterns in score plot. 
Maturity Variable 
[12] 
The variable indicating the evolution of a batch. It is used 
to understand how far the batch is evolved compared to 
the historical batches 
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Term Definition 
PAT
  
[2] A system for designing, analyzing, and controlling 
manufacturing through timely measurements (i.e., during 
processing) of critical quality and performance attributes 
of raw and in-process materials and processes with the 
goal of ensuring final product quality 
Process Analytics 
[2] 
Chemical or Physical analysis of material in the process 
through the use of an in-line or on-line analyzer 
Process Validation 
[17]  
Establishing by objective evidence that a process 
consistently produces a result or product meeting its 
predetermined specifications. 
Score Plot [12] It is a summary of observations (batches) 
SIMCA [19] Software application supporting creation of multivariate 
models 
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ACRONYMNS 
 
Abbreviation Meaning 
ACPS Advisory Committee for Pharmaceutical 
Science  
API Active Pharmaceutical Ingredient 
ASTM American Society of Testing Materials 
BLA Biological License Application 
BSPC Batch statistical process control 
CAPA Corrective Action and Preventative Action 
CBER Center for Biological Evaluation and Research 
CDER Center for Drug Evaluation and Research 
CFR Code of Federal Regulations 
cGMP Current Good Manufacturing Practices 
CMC Chemistry, Manufacturing and Controls 
CQA Critical to Quality Attributes 
CVM Center for Veterinary Medicine 
DOE Design of experiments 
DModX Distance to the model in the X-data 
DS Drug Substance 
ERP Enterprise Resource Planning systems 
FDA Food and Drug Administration 
ICH International Conference on Harmonization  
LIMS Laboratory Information Management system 
MES Manufacturing Execution system 
MSPC Multivariate statistical process control 
MVDA Multivariate Data Analysis  
NDA New Drug Application 
ONDC Office of New Drug Chemistry 
OOC Out of control 
ORA Office of Regulatory Affairs 
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Abbreviation Meaning 
QbD Quality by Design 
PAT Process Analytical Technology 
PAI Pre-Approval Inspection 
PCA Principal Component Analysis 
PLS Partial Least Squares or Projection to Latent Structures 
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ABSTRACT 
 
Conventional pharmaceutical and biopharmaceutical manufacturing processes are 
accomplished using batch processing coupled with laboratory testing of off-line samples 
to determine the quality of the product prior to release. This approach is successful and 
can continue to be employed. However; due to recent technological developments, 
significant opportunities are available for improving the biological manufacturing 
processes. These opportunities include innovation in process development, process 
analysis, and process control by applying and using Quality by Design (QbD), Process 
Analytical Technology (PAT) and statistical tools. The regulatory agencies have given 
overwhelming support to these concepts throughout the last decade. They took initiative 
to support these innovation and technological developments by revising and approving 
guidance documents such as cGMPs for the 21
st
 Century: A Risk Based Approach [1], 
PAT framework [2], International Conference on Harmonization (ICH) Q8, Q9, Q10 [3, 
4, 5], Food and Drug Administration’s (FDA’s) 2011 guidance for Process Validation [6] 
and lastly ICH Q11 in 2012 [7]. These guidelines are continuously setting new industry 
trends as well as continuing to raise expectations. This study was focused on the use of a 
multivariate statistical data analysis tool for real-time process monitoring and its 
validation test cases to support good manufacturing practice (GMP) decisions. It also 
discusses case studies to demonstrate how a batch can be monitored using multivariate 
(MV) models to quickly identify out of trend results or batch failures real-time.  Data 
from one biologics commercial manufacturing process is used for the creation of MV 
models to highlight the industrial application of the tool. The business benefits of 
implementing real-time multivariate statistical analysis in a GMP environment are also 
discussed.      
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INTRODUCTION 
 
Most of the existing manufacturing processes for biological product at scale are not 
designed for real-time process monitoring. In order to enable real-time process 
monitoring capabilities, modifications to existing facilities need to be modified by 
installation of PAT with incorporation of QbD principles. In addition to technological 
modifications, various computerized systems must be implemented or modified for 
acquisition of large quantities of process data in real-time.  Software applications to 
analyze this data and the statistical methods to process and generate the results are 
additionally required. This entire data acquisition, analysis and processing system is 
termed as “Real-Time Statistical Process Monitoring System”.   
A typical biologics manufacturing process is comprised of a series of upstream and 
downstream unit operations. The upstream manufacturing process (a.k.a. fermentation 
process) consists of a master cell bank vial thaw, cell line expansion in a shake flask to 
shaker bottles or bags, seed bioreactors, production bioreactors and centrifugations for 
harvesting protein. The downstream manufacturing process (a.k.a purification process) 
consists of various chromatography columns, viral inactivation, ultra-
filtration/diafiltration (UF/DF), and viral filtration for purification and separation of 
therapeutic proteins prior to final fill-finish operations.  
Each unit operation is comprised of multiple phases. Each phase is operated by multiple 
process parameters or variables.  These parameters are categorized into input and output 
parameters. The input parameters are evaluated in the operating space and 
characterization studies and are maintained within the known operating ranges to achieve 
the desired output. However, the output parameters (a.k.a performance parameters) have 
a pre-set acceptance criteria to ensure that the process delivers consistent results every 
time.  
For every biological process batch, there are many process variables measured during the 
course of production. It is important to make sure that each variable is operating within it 
operating range to ensure process performance consistency and product quality..  
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The suggested PAT framework using combination of following PAT tools includes: 
I. Multivariate (more than one variable) data acquisition and analysis 
II. Process and endpoint monitoring and control tools 
III. Continuous improvement and knowledge management tools 
 
The multivariate statistical process monitoring system efficiently monitors many 
variables at the same time by utilizing multivariate charts. The system also explains how 
these variables are changing in correlation with performance variables.  
The goal of this study was to demonstrate how above stated  PAT tools can be utilized to 
ensure continued process verification as outlined in FDA’s 2011 process validation 
guidelines [6] for making critical manufacturing decisions in real-time. 
In order to collect data for the multivariate data analysis (MVDA), modern process 
analyzers such as pH, temperature, agitation, dissolved O2, CO2, and cell density probes 
must be installed so that the process information can be gathered at regular intervals. 
Various software applications store and maintain this process data into databases 
enabling extraction of meaningful and critical process information from this data.   
This study focused on the use of multivariate analysis tool as outlined in PAT framework 
by using SIMCA software to create multivariate models for real-time process monitoring. 
The data collection and data mining process is a critical step which required installation 
of multiple software interfaces for linking the software databases, database modifications, 
and creation of trigger tags, timers, batch tags and monitoring markers. The three 
dimensional data extracted from the databases must be unfolded and saved in a specific 
format so that it can be used by the SIMCA software for the creation of batch evolution 
and batch level models.    
Various MV models are generated using the successful performance batches from the 
historical databases. Two popular and commonly used MVDA methods such as  principal 
components analysis (PCA) and partial least squares (PLS) were employed to 
demonstrate the use of PAT tool [2, 9, 10]. Then new batches were tracked against these 
 48 
 
models to ensure process consistency and detect deviations or process failures in real-
time.   
This study proved that PAT tools can be used to achieve continued process verification 
which meets  the lifecycle approach in FDA’s process validation guideline [6] and 
adaption of new mantra that the “Process validation should not be viewed as a one-off 
event. A lifecycle approach should be applied linking product and process development, 
validation of the commercial manufacturing process and maintenance of the process in a 
state of control during routine commercial production” [15]. 
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MATERIALS AND METHODS 
 
MATERIALS 
SIMCA Software v13.0.3 [8]: The SIMCA software version 13.0.3 was utilized for the 
creation of statistical MV models.  This software was developed by Umetrics.  
This software was used to create a design of experiments and multivariate data analysis. 
This tool transforms data into information, which can be seen in the form of color coded 
graphical control charts to enable the process analyst to make correct decisions in real- 
time.  
 
Historical data from consistent successful process batches (batches which have minimum 
deviations) were used from a biological manufacturing process. The data was extracted 
from the historical databases by making configurations, tags, scan rates, and compression 
settings to the source system. This data was pre-treated and organized in the appropriate 
format prior to importing into the SIMCA software for the creation of multivariate 
models.  
METHODS 
This study was conducted by using the data from a commercial biological manufacturing 
facility. The commercial biological manufacturing process was enabled with various 
modern process analyzers and was equipped with both a distributed control system 
(Delta-V) system and a plant data historian to collect the process data. The MVDA tool 
was linked to the process databases to acquire the process data.  Modifications were made 
to the existing databases for the appropriate collection of data from the unit operations. 
The case studies presented were focused on one upstream unit operation (i.e., bioreactor) 
and one downstream unit operation (i.e. UF/DF).   
The data set used for the bioreactor and UF/DF unit operations, to develop empirical 
models for multivariate monitoring purposes, were gathered from one of the existing 
products. The data were modified (normalized for propriety reasons) as necessary prior to 
using it for the creation of MV models in SIMCA.    
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The bioreactor and UF/DF unit operations were monitored using the parameters listed in 
Table 1 and Table 2. These unit operations were connected to the DeltaV system to 
collect the process data. The process database was connected to both DeltaV and a plant 
data historian and the historical and current batch data was saved continuously. The plant 
data historian was configured with the correct tags to enable advanced monitoring [11]. 
Along with online data collection, cell viability and viable cell density data were also 
collected from off-line measurements to check the process performance at every twenty-
four hour interval during the course of the unit operation. The configuration of trigger 
tags, timers and batch tags were made as required to get all the relevant batch and 
continuous process data from the historical databases. 
 
The on-line data was collected at 15 minutes intervals for the bioreactor unit operation 
and at 10 second intervals for the UF/DF unit operation. The data from fifteen batches 
were used for the creation of the MV model and control charts for the real-time statistical 
process monitoring. The historical batches which had lowest number of deviations and 
alarm conditions were selected as an input for the MV model creation to represent 
inherent process variability also known as common cause variation. The goal for this 
rational subgroup selection criterion was to create a reference MV model.  The MV 
model created the average and ± 3 standard deviation confidence limits for the control 
charts about the scores and raw variable trajectories. Two new batches were projected 
over this model for testing the effectiveness of the real-time monitoring application.  An 
artificial disturbance was introduced into one of the two new batch data generated by 
making changes to certain variables in order to test if the MV model could detect the 
changes.  This study was used to prove if the real-time multivariate system can monitor 
the state of control for the new batches, detect any process failures due to sensor 
malfunction and end point monitoring.  
 
A similar concept of creating MV models and process monitoring in real-time was 
utilized for all the unit operations. The deployment of this project into cGMP 
environment requires qualification and validation of the computerized systems per CFR 
Title 21 [12], Software Validation Guidance [13] and Part 11 Guidance [14]. The 
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validation of the real-time process monitoring system was performed enabling the system 
use in the cGMP environment to achieve continued process verification meeting FDA’s 
process validation lifecycle approach.  
 
ASSUMPTIONS 
I. SIMCA software version 13.0.3 from Umetrics was utilized for the creation of 
statistical multivariate models. Therefore, the calculations performed for the 
generation of multivariate models in SIMCA software were correct because 
SIMCA was a commercial-of-the-shelf (COTS) application.  
II. The SIMCA graphics and control charts calculated by the software were accurate.  
III. The data used for MV model creation was collected from the validated 
commercial manufacturing process by creating batch identifiers, monitoring 
markers from historical database. 
IV. The data collection and data mining method for each unit operation to feed into 
the SIMCA software for the creation of MV models is identical.  
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MV MODEL CREATION 
In this section, the MVDA methods such as PCA and PLS were used to create batch 
evolution model (BEM) and batch level model (BLM) for the bioreactor and UF/DF unit 
operations for a legacy biological manufacturing process. The data set used for the 
bioreactor and Ultra –Filtration and Di-Filtration (UF/DF) unit operations to develop the 
empirical models for multivariate monitoring purposes was gathered from an existing 
biologics commercial manufacturing facility.   
Data selection criteria:  
The bioreactor and UF/DF unit operation are equipped with multiple online sensors as 
shown in Tables 1 and 2.  This state of the art data collection capability enables real-time 
monitoring of the unit operations. The data collected from these sensors were 
preprocessed and arranged in a specific data format to import into the SIMCA software 
for the creation multivariate statistical process models for data acquisition and analysis. 
MV for Bioreactor:  
The dataset used in model building contained data for N=17 batches. Out of these, fifteen 
batches were selected for the creation of MV model. The batch selection criteria were to 
include a little variability among the batches used for the UF/DF process. The main 
objective of the case study was to create a MV model so that it could be used as a 
reference to monitor new batches in process and identify whether those batches are in 
multivariate control. Fourteen variables (J=14) were monitored and the data was collected 
at fifteen minute interval, giving a total of ~K = 279 time points. The total duration of the 
unit operation was 68 hours, 30 minutes. The bioreactor unit operation was assumed as a 
single phase process.   
MV for UF/DF: The dataset contained data for N=17 batches. Out of these, fifteen 
batches were selected for the creation of a MV model. The batch selection criteria were to 
include a little variability among the batches used for the UF/DF process. The main 
objective of the study was to create a MV model so that it could be used as a reference to 
monitor new batches in process and identify whether those batches were in multivariate 
control.  Nineteen variables (J=19) were monitored and the data was collected at ten 
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second interval, giving a total of K = 817 time points. The total duration of the unit 
operation was 2 hours: 31 minutes: 10 seconds. The UF/DF unit operation was comprised 
of three phases which include concentration, diafiltration and recovery. Purpose of this 
unit operation is to concentrate and buffer exchange via tangential flow filtration. 
Following concentration and diafiltration, the product pool is recovered by filtering it 
through 0.2µ membrane filter. 
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Table 1: Bioreactor Variables Monitored 
Variable 
Name 
Unit of 
Measure 
Variable 
Type 
Variable  
Class 
Variable Use 
Dissolved O2 % Operating Input 
Dissolved oxygen is monitored 
as a measure of cell culture 
performance 
Culture pH pH units Operating Input 
pH affects final viable cell 
density 
Air flow sLPM Operating Input 
Air flow is monitored as a 
measure of cell culture 
performance 
O2 flow sLPM Operating Input 
O2 flow is monitored as a 
measure of cell culture 
performance 
CO2 flow sLPM Operating Input 
CO2 flow is monitored as a 
measure of cell culture 
performance 
Bioreactor 
level 
L Operating Input 
Bioreactor level is monitored to 
maintain consistent volume 
Agitation RPM Operating Input 
Agitation maintains a 
homogenous solution and 
oxygen transfer to the cells 
Vessel 
pressure 
psig Operating Input 
Pressure influences mass 
transfer and mitigates 
contamination 
Temperature °C Operating Input 
Temperature (controlling 
probe) excursions  can impact 
final viable cell density and 
viability 
Culture 
duration 
days Operating Input 
Culture duration affects final 
viable cell density and is the 
maturity variable 
Temperature 
probe 
difference (A-
B) 
°C Operating Input 
Temperature probe difference 
(A-B) is monitored to detect 
equipment drift or malfunction 
VCD (Viable 
Cell Density) 
10
6
 
cells/mL 
Performance Output 
VCD is monitored as a measure 
of cell culture performance. 
Viability % Performance Output 
Viability is monitored as a 
measure of cell culture 
performance. 
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Table 2: UF/DF Variables Monitored 
Variable Name 
Unit of 
Measure 
Variable 
Type 
Variable  
Class 
Variable Use 
Feed pressure psig Operating Input 
Feed pressure is monitored to 
detect excursions in pressure 
Retentate pressure psig Operating Input 
Retentate pressure is 
monitored to detect 
excursions in pressure 
Permeate pressure psig Operating Input 
Permeate pressure is 
monitored to detect 
excursions in pressure 
Transmembrane 
pressure (TMP) 
psig Operating Input 
TMP is monitored to detect 
any excursions in pressure 
Feed flow LPM Operating Input 
Feed flow is monitored to 
detect any excursions in flow 
rate 
Retentate flow LPM Operating Input 
Retentate flow is monitored 
to detect any excursions in 
flow rate 
Permeate flow LPM Operating Input 
Permeate flow  is monitored 
to detect any excursions in 
flow rate 
Feed Retentate DP  psig Operating Input 
Feed retentate pressure is 
monitored to detect 
differential pressure 
Permeate flux L/hr/m2 Operating Input 
Permeate flux (permeate flow 
rate normalized by membrane 
area) is monitored to detect 
excursions in flow rate 
Permeate UV 
(ultra violet) 
AU Operating Input 
Permeate UV is monitored to 
detect product loss during 
UF/DF II 
Permeate 
conductivity 
mS/cm Operating Input 
Permeate conductivity is 
monitored to ensure product 
conductivity targets 
Concentration 
factor 
N/A Operating Input 
Concentration factor is 
monitored to ensure 
concentration targets are met 
Diafiltration 
Factor 
L Operating Input 
A minimum number of 
diavolumes are required to 
meet pH and conductivity 
specifications for the UF/DF 
II Pool 
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Variable Name 
Unit of 
Measure 
Variable 
Type 
Variable  
Class 
Variable Use 
Feed flow process 
totalizer 
L Operating Input 
Feed flow totalizer is 
monitored to ensure 
concentration and 
diafiltration targets are met 
Permeate flow 
process totalizer 
L Operating Input 
Permeate flow totalizer is 
monitored to detect any 
excursions in the total 
permeate volume 
Retentate flow 
process totalizer 
L Operating Input 
Retentate flow totalizer is 
monitored to ensure 
concentration and 
diafiltration targets are met 
and is the maturity variable 
Permeate control 
valve 
% Operating Input 
Permeate control valve is 
monitored as a controller 
output 
Retentate control 
valve 
% Operating Input 
Retentate control valve is 
monitored as a controller 
output 
Step yield % Performance Output 
Step yield is monitored as a 
measure of UF/DF 
performance. 
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The data obtained from the above variables was pre-processed prior to use in the creation 
of the MV model. Multivariate methods are maximum variance projection methods. A 
variable with a large variance is more likely to be expressed in the modeling than a low-
variance variable. In order to give equal weight to all the variables, the data from the 
variables required standardization. The unit variance scaling [16] was chosen for these 
case studies. For example, DO2 values vary from ~ 30 to 90 ranges whereas Air flow 
values vary from 0 to 1 for bioreactor. If we do not perform scaling then the DO2 variable 
will have very high variance and it will have an impact on the model as compared to Air 
flow. Therefore, the MV model without data scaling may not be accurate.  
Two levels of batch monitoring were employed; the BEM and BLM were implemented 
by unfolding the three-way matrix into two-way matrix as shown in Figure 1a and 2b 
[17]. 
BEM: The goal of BEM was to develop a model of the desired batches and monitor new 
batches against this model to determine if they were evolving within the confidence 
limits. The data generated by a batch process was arranged in data blocks as shown in 
Figure 1a and 2b [17]. The batches were depicted as “I”, variables depicted as “J” and 
time points depicted as “K”.  In order to execute BEM, the three way batch data table was 
unfolded in such a way that the direction of the variable was preserved as shown in 
Figure 1a [17]. The resulting two-way matrix then had “I *J” rows and K columns. Each 
row contains data points Xijk from a single batch observation (batch I, time K and 
variable J). The regression was made against local batch time, the resulting PLS scores 
reflected linear t1, t2, and t3 relationships to local time batch time. A PCA on the three 
way data matrix showed how the individual observations related to each other [10]. 
Each batch had a different completion time resulting in an unequal number of 
measurements [18]. SIMCA software resolved this issue by auto generating a dummy y 
variable reflecting relative local batch time which was a dummy variable called “$Time”, 
to align the unequal batches to have the same length. The value of $Time predicted by the 
PLS model was used to indicate how far a batch has evolved [8].  The fifteen batches 
were used for the creation of the reference PLS model of X data matrix versus local time 
($Time).  
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Figure 1a: Unfolding Three Way Data Matrix [Source: 17]. The three-way table of 
historical batch process data comprises “I”, J variables and K time points. In the 
BEM, this three-way data table was unfolded by preserving the variable direction. 
This gave a two-way matrix with I*K rows and J columns. Each row contained 
data points Xijk from a single batch evolution. Figure 1b: The three-way table of 
historical batch process data comprises “I”, J variables and K time points. In the 
BLM, this three-way data table was unfolded by preserving the batch direction. 
This gave a two-way matrix with I rows and J*K columns. Each row contained 
data points from one single batch. 
BLM: In batch level modeling, all the data are from input variable matrix (X) and output 
variable matrix (Y) is available. Therefore, the data from the whole batch is used to 
create a model. The aim of the batch level model is to verify whether the new batch is 
within multivariable control. The data generated is unfolded in such a way that the 
direction of the batch is preserved. The resulting two-way matrix then has “I*K” rows 
and J columns as shown in Figure 1b [17]. Another important objective of batch level 
model is to understand how Y (output) variable is influenced by the X (input) variables 
[10]. 
 
Diagnostics and Interpretation Controls Charts for the Bioreactor Unit Operation MV 
model:  
 
BEM Model: The new BEM model created for the bioreactor unit operation shows that 
the model is fits well. The original variables when projected on these new components, 
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results into scores which are new co-ordinates that gets plotted as t1, t2, t3 to a local batch 
time ($Time). This PLS model shows how the X-matrix input variables relate to each 
other in respective score plot and the loading plot Figure 2 and 3. The first principal 
component (PC) explains the maximum variation in X and then subsequent PC’s explain 
the remaining variation in a descending order. The general expectation is that at least 
75% to 85% of the variation must be accounted for by a good model [10]. This is because 
the scores of BEM model are used at the BLM to predict the output variable.  
Scatter Plot t1 vs. t2 (Bioreactor): 
The score plot is a map of the observations. Figure 2 displays the score plot for t1 vs.  t2 
scores. These are the new variables summarizing the X-variable matrix. The scores are 
orthogonal, (i.e., completely independent of each other). The score t1 (first component) 
explains the largest variation of the X space, followed by t2. The scatter plot of t1 vs. t2 is 
a window in the X space, displaying how the X observations are situated with respect to 
each other. This plot in Figure 3 shows the possible presence of outliers, similarities, and 
other patterns in the data. 
The score plot shows that there is a strong behavioral similarity among the variables from 
all the batches. Each batch starts in the top left hand quadrant and ends in the top right 
quadrant.  
 
Figure 2: The Score Plot (BEM) for the bioreactor unit operation. The plot is 
created using the scores of first two principal components. The vertical axis 
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depicts t2 scores and the horizontal axis depicts t1 scores. The score plot shows 
that all the batches are aligned properly and fitting on 95% confidence ecllipse. 
Loadings Plot W*C [1] vs. W*C [1]:  
The loading plot shows this model can be furthered analyzed by Figure 3. It reveals that 
the response variable ($Time) is positively correlated with O2 flow and Culture duration.  
The response variable is less correlated with Air Flow. There is a strong similarity 
between the behaviors of temperature, agitation, pressure and the bioreactor level.  Other 
variables like CO2 flow, and bioreactor level are negatively correlated. 
 
Figure 3: The Loading Plot (BEM) for the bioreactor unit operation. The plot is 
created using the loadings of first two principal components. The vertical axis 
depicts ‘w*c [2]’ loadings and the horizontal axis depicts ‘w*c [1]’ loadings. The 
plot shows how variables are correlated to each other.  
The scores batch control chart displays that the selected score values (t1) over time for all 
the 15 batches. The chart depicts the average batch (green) and the ±3 standard deviation 
(red). Figure 4 and 5 show the score contributions for scores t1 and t2. The t1 score plot 
demonstrates that all the batches start with low scores and then increase steadily until the 
termination. Whereas, for t2 scores, all of the batches move steady and end the same way. 
All of the fifteen reference batches behave well between the ±3 standard deviation and 
around the average for both t1 and t2 scores.  
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 Figure 4: The PC 1 Score Batch Plot for the bioreactor unit operation. The fifteen 
batch plot for PC 1 show that all batches are ending in a similar fashion within the 
±3 standard deviation confidence limit. 
 
Figure 5:  The PC 2 Score Batch Plot for the bioreactor unit operation. The fifteen 
batch plot for PC 2 shows that all batches are ending in a similar fashion within 
the ±3 standard deviation confidence limit. 
Hotelling T
2 
chart in figure 6 demonstrates that all the data from all the variables are 
within the score dimension. 
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Figure 6: Hotelling T2 Plot for the bioreactor unit operation. The plot shows that 
all data from all variables is within the score dimension. 
BLM Model: In batch level modelling, the entire batch data from all input and output 
variables are used to create the PLS model. In order to accomplish BLM modelling, the 
three-way batch data table is unfolded as shown in Figure 2b. The data is unfolded in 
such a way that each row in the data table represents one whole batch as shown in Figure 
2b [17].  The unfolded data from X matrix (input variables) is regressed with unfolded 
data from the Y matrix (output variables). The data are arranged in such a way that the 
direction of the batch is preserved. The three-way data is arranged in two way matrix 
which had N*KJ rows (batches) and column (variables). There are two output variables 
(i.e. viable cell density and cell viability). The fifteen batches used for the creation of the 
reference PLS model of X data matrix versus Y data matrix can now be used to classify 
new batches still under development as to whether they are in multivariable control and 
see how Y variables are influenced by X variables[10]. The bioreactor batch level PLS 
model as shown in Figure 7, demonstrates that all batches are evenly scattered and are 
within the 95% confidence interval ellipse. Batch# 1001 is on the ellipse and is within the 
95% confidence limit. The diagnostics charts, Hotelling’s T2 and DModX, charts as 
shown in (Figure 8 and 9) were well with within the confidence limits for all fifteen 
batches. 
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Figure 7: The Batch Level Score Plot for 15 Batches. The plot displays that all 
batches are well within the 95% ecllipse.  
 
Figure 8: The Hotelling’s T2 Batch Level Plot for 15 batches. The plot displays 
that all batches are well within the 95% confidence limit.  
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Figure 9: The DModX Batch Level Plot for 15 batches. The plot displays that all 
batches are well within the critical limit of 0.05.  
Diagnostics and Interpretation Controls Charts for MV model for UF/DF:  
 
BEM Model: The new BEM model created for UF/DF unit operation shows that the 
model is fitted well for concentration, diafiltration and recovery phases. The original 
variables when projected on these new components, results in scores which are new 
variables that gets plotted as t1, t2, t3 to a local batch time ($Time). This PLS model 
shows how the X-matrix input variables relate to each other in both a respective score 
plot and the loading plot (Figure 10) for concentration phase.  
 
Figure 10: The Score Plot for Concentration Phase for the UF/DF unit operation. 
The score plot is created using the scores of the first two principal components. 
Vertical axis depicts t2 scores and horizontal axis depicts t1 scores. The score plot 
shows that all the batches are aligned properly and fit the 95% confidence limit 
ecllipse. 
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Loadings Plot W*C [1] Vs. W*C [1]:  
The loading plot demonstrates that this model can be further analyzed by interpretation of 
Figure 11. It reveals that the response maturity variable ($Time) is positively correlated 
with the retentate flow process totalizer, permeate flow, process totalizer, feed flow and 
concentration factor. These variables steadily increase with time. All other variables 
maintain somewhat steady state and are reasonably co-related with each other except for 
retentate pressure which is negatively correlated as it shows a decreasing trend with time.    
 
Figure 11: The Loading Plot for UF/DF. The BEM plot is created using the 
loadings of first two principal components. The vertical axis depicts ‘w*c [2]’ 
loadings and the horizontal axis depicts ‘w*c [1]’ loadings. The plot shows how 
the variables correlate to each other. Variables like retentate flow process totalizer 
permeate flow process totalizer, feed flow, and concentration factor are strongly 
correlated with the maturity variable. Retentate flow control negatively correlates 
with the maturity variable. 
The scores batch control chart displays the selected score value (t1) over time for all 
fifteen batches. The chart also shows the average batch (green) and the ±3 standard 
deviation (red). Figure 12 shows the score contribution for t1 scores. The t1 score plots 
demonstrate that all batches start with low scores and then steadily increase until 
termination. All of the fifteen reference batches behave well between ±3 standard 
deviation and around the average for first PC.  
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Figure 12: The PC 1 Score Batch Plot for the UF/DF unit operation.  The plot 
shows that all fifteen batches are ending in a similar fashion within ±3 standard 
deviation confidence limit. 
BLM Model: In batch level modelling, the entire batch data from input variables and 
output variables are used to create the PLS model. In order to accomplish BLM 
modelling, the three-way batch data table is unfolded as shown in Figure 2b [17]. The 
data is unfolded and arranged as explained in the bioreactor BLM section.  In the case 
study for UF/DF, the output variable is step yield. The fifteen batches used for the 
creation of the reference PLS model of X data matrix versus Y data matrix can now be 
used to classify new batches that still under development and demonstrate how Y 
variables are influenced by X variables[10]. The UF/DF batch level PLS model as shown 
in Figure 13, using the first two components demonstrate that all the batches are evenly 
scattered and are within the 95% confidence interval ellipse. When the diagnostics charts 
like Hotelling’s T2 and DModX are evaluated, charts, (Figures 14 and 15), are well with 
within the confidence limits for all fifteen batches. 
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Figure 13: The UF/DF Batch Level Score Plot for 15 batches. The plot shows that 
all batches are well within the 95% ecllipse.  
 
 
Figure 14: The UF/DF Hotelling’s T2 Batch Level Plot for 15 batches. The plot 
demonstrates that all batches are well within the 95% confidence limit.  
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Figure 15: The UF/DF DModX Batch Level Plot for 15 batches. The plot 
demonstrates that all batches are well within the critical limit of 0.05.  
In the previous section, the multivariate BEM and BLM models were created by using 
fifteen good batches. The control limits and the averages were established using the data 
from the model batches. The following sections will demonstrate how these models can 
be used to monitor the new batches in process. If the new batch is a good batch then it is 
expected to evolve with in the confidence limits. This can be seen on the control charts. 
At the same time, if for any reason, there is a deviation then the cause and the source of 
the deviation can be tracked using the control charts. Introduction of this tool into the 
GMP manufacturing facility equipped with on-line data collection technologies can 
monitor every new batch in real-time to provide continuous improvement data as well as 
a scientific knowledge management opportunities and additionally meeting the FDA’s 
third stage, continued process verification life cycle approach.    
In order to test the real-time process monitoring system to ensure continued process 
verification, two new batches (Batch# 1016 and 1017 for the bioreactor unit operation 
and batch# 116 and 117 for the UF/DF unit operation) were selected for each of the 
bioreactor and UF/DF unit operations. One new batch selected for the study was a good 
batch and the second new batch was deliberately modified (after the fact for simulation 
purposes) by making changes to feed pressure and feed flow to determine if the changes 
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can be detected by the real-time process monitoring system.  Case studies were used as an 
example to demonstrate how the real-time process monitoring system can be used in the 
manufacturing process for continued process verification, detect process failures in the 
new batches due to sensor malfunction or process related failures and root cause analysis 
and process control. 
  
 70 
 
CASE STUDY 1: MONITORING STATE OF CONTROL FOR A NEW 
BIOREACTOR PROCESS BATCH 
In this example, a new batch (batch# 1016) was projected on the MV model created using 
fifteen good batches to see if this batch was running in the state of control. The batch 
score plot in Figure 16 shows that the batch# 1016 shown in dark red color was well 
within the 95% confidence limit. The score plot shows that batch# 1016 was a good 
batch. 
 
Figure 16:  The Batch Score Plot for bioreactor batch# 1016. Batch# 1016 was 
projected on the model with other batches. Batch# 1016 was highlighted in red. 
The score plot shows that batch# 1016 was a good batch because it was well 
within the 95% confidence limit.  
The batch control score plot for batch# 1016 in Figure 17 shows that the batch was within 
± 3 standard deviation. Therefore, it was a good batch. 
 
Figure 17: The Batch Control Plot for bioreactor Batch 1016. It shows that it was 
within ± 3 standard deviation. Therefore, it was a good batch. 
 71 
 
CASE STUDY 2: DETECT SENSOR MALFUNCTION FAILURE FOR NEW 
BIOREACTOR PROCESS BATCH 
The intent of this test was to determine if a sensor malfunction can be detected by the 
MV model. The faulty sensor can show the incorrect values while the batch was 
evolving. The pH and temperature raw data from the batch# 1016 was modified to show 
that the pH and temperature sensors were faulty. The pH and temperature raw data were 
deliberately changed at several time points in the excel datasheet prior to importing it into 
the SIMCA application to project on the MV model.  The new batch (batch# 1017) was 
then projected on the MV model.  The batch score plot in Figure 18 and batch control 
score plot in Figure 19 clearly show that batch# 1017 was outside the model space.  
 
Figure 18: The Batch Score Plot for bioreactor batch# 1017. Batch# 1017 was 
shown in red and was outside of the 95% confidence limit. 
 
Figure 19: The Batch Control Plot for bioreactor batch# 1017. The control plot 
shows that it was going out of ± 3 standard deviation confidence limits at several 
places.  
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The variable batch plots for culture pH in Figure 20 and for temperature in Figure 21 
demonstrate the time points when the batch was out of confidence limits.   
 
Figure 20: Culture pH Variable Batch Plot for batch# 1017. The plot shows the 
exact time when the batch was outside of the ± 3 standard deviation confidence 
limit.  
 
Figure 21: Temperature Variable batch Plot for batch# 1017. The plot shows the 
exact time when the batch was outside of the ± 3 standard deviation confidence 
limit. 
Hotelling’s T2 and DModX charts in Figure 22 and Figure 23 also show that batch# 1017 
depicted in yellow color was outside of the ± 3 standard deviation and Dcrit (0.05) shown 
in red. The variable batch plot demonstrates that the time points when the pH and the 
temperature variables were outside of the confidence limits.   
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Figure 22: Hotelling’s T2 Plot for 1017. The plot shows the time when the batch 
was outside of the 95% critical limit. 
 
Figure 23: DModX Plot for 1017. The plot shows the exact time when the batch 
was outside of ± 3 standard deviation confidence limit. 
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CASE STUDY 3: MONITOR THE STATE OF CONTROL FOR A NEW UF/DF 
BATCH 
In this example, a new batch (batch# 116) was projected on MV model created using 
fifteen successful batches to determine if this batch was running in a state of control. The 
batch score plot in Figure 24 shows that the batch# 116 shown in dark red color was 
moving within the ± 3 standard deviations shown in red and around the average shown in 
green. 
 
Figure 24: Batch Score Plot for UF/DF batch# 116. The plot was projected on the 
model with other batches in the model and highlighted in red. The score plot 
shows that batch# 116 was a good batch because it was well within the 95% 
confidence limit.  
Batch control plot for batch# 116 in Figure 17 shows that the batch was within the 
confidence limits. Therefore, it is considered a good batch. 
 
Figure 25: The Batch Control Plot for UF/DF batch# 116. The plot shows that 
batch 116 was within ± 3 standard deviation. Therefore, it was a good batch. 
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CASE STUDY 4: DETECTION OF SENSOR MALFUNCTION FAILURE FOR NEW 
IN A UF/DF BATCH  
The intent of this test was to demonstrate if a sensor malfunction can be detected by the 
MV model. The faulty sensor can show the incorrect values while the batch was 
evolving. The feed pressure and feed flow raw data from batch# 116 was modified to 
show that the feed pressure and feed flow were faulty. The feed pressure and feed flow 
raw data were deliberately changed at multiple time points (after the fact for simulation 
purposes). The new batch# 117 was then projected on the MV model.  The batch 
contribution score plot in Figure 26 clearly showed that batch# 117 was going outside of 
± 3 standard deviation confidence limits at several places. The batch variable contribution 
plot for feed pressure in Figure 27 showed the exact time point where the variable was 
outside of the of ± 3 standard deviation confidence limits.   
 
Figure 26: Batch Control Score plot for UF/DF batch# 117. The plot shows 
batch# 117 is going outside of ± 3 standard deviation at several places.  
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The variable batch plots for feed pressure in Figure 27 and for feed flow in Figure 28 
showed the exact time points when the these two variables were outside of  ± 3 standard 
deviation confidence limits.   
 
Figure 27: Feed Pressure Variable Batch Plot for 117. The plot shows the time 
points when the feed pressure exceeded the ± 3 standard deviation confidence 
limits.  
 
Figure 28: Feed Flow Variable Batch Plot for 117. The plot shows the time when 
the feed flow exceeded the ± 3 standard deviation confidence limit.  
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VALIDATION OF MULTIVARIATE STATISTICAL MONITORING SYSTEM 
 
An existing commercial manufacturing facility can be PAT enabled by installation of 
state of the art on-line sensors, data management system and data analyzing computer 
hardware and software systems. This vast amount of data collected from a ten second 
interval to fifteen minute intervals from different unit operations is saved in databases. 
The entire system consists of multiple data servers, network components, software 
interfaces, and software applications for multivariate analysis. In this study, the SIMCA 
software was used for the multivariate model creation which was connected to the 
network via several related software interfaces.  All together this entire system becomes 
an automated computerized system. As per FDA’s software validation guidance [13], 
prior to using any computerized system in a cGMP environment, it must be qualified and 
validated. The cGMP guideline outlines that “Any software used to automate any part of 
the device production process or any part of the quality system must be validated for its 
intended use, as required by 21 CFR §820.70(i)”. Validation is necessary to establish 
documented evidence to provide a high degree of assurance that the system will 
consistently operate according to pre-defined requirements and design specifications [12]. 
 
The SIMCA software is Part 11 compliant software. In order to utilize it in the cGMP 
environment, it must undergo validation per Computer Validation Guidelines [13] and 
Part 11 guidelines [14]. For the validation of a computerized system, several documents 
are generated, executed and approved by appropriate stake holders in the GMP facility.  
All validation related documents and the test cases for the validation of real-time process 
monitoring system are generated per software validation and Part 11 guidance.  
The following section outlines the documents and test cases generated for the validation 
of the real-time process monitoring system. 
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Validation Plan 
The purpose of the Validation Plan (VP) was to define the overall validation approach, 
roles and responsibilities, required deliverables, test strategy, and key decisions related to 
the validation.  The VP provides the basis for scheduling of the validation activities and 
documentation was required in order to meet the acceptance criteria specified in the 
Requirements Specification and Design Specification documents. It also outlines test 
documents such as Installation Qualification (IQ), Operational Qualification (IQ), and 
Performance Qualification (PQ) for documenting the installation verifications of the 
modifications/changes to historical databases, software interfaces, database configuration, 
server configurations, network connections and SIMCA software. The VP also outlines 
the requirements specifications (RSs) and design specifications (DSs), operation and 
performance testing documents, requirement traceability matrix (RTM), and validation 
summary reports (VSRs). 
When any validation project is rolled out on a large scale in the GMP environment, IS, 
automation, project management, process development, manufacturing, validation and 
quality assurance (QA) teams are involved. Therefore, it is very critical to outline the 
roles and responsibilities of every group for tracking and successful implementation of 
these tasks. 
 
Validation Strategy 
Validation of the MVDA system was implemented to establish documented evidence that 
the system will consistently provide reliable and robust data for monitoring of 
manufacturing purposes. The main deliverables that specify and document the testing of 
the system were RS, DS, IQ, OQ, and PQ documents. The RTM and VSR were written at 
the end of validation testing. The RTM demonstrated that the requirements were mapped 
to the RS/DS and to the corresponding test cases in the validation protocols. The VSR 
was generated to outline the completion of validation deliverables.  
A risk management process outlined in Figure 32, GAMP-5 [19] is utilized while 
determining the extent of testing performed to validate the MVDA system.  
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Figure 29: Five ‘Risk Management Process’ steps [Source: 19] shows how the 
risk assessment is performed to determine the extent of validation testing 
required. 
 
There are two basic classes of software testing: black box testing and white box testing 
[20]: 
 Black box testing (also called functional testing) is testing that ignores the 
internal mechanism of a system or component and focuses solely on the 
outputs generated in response to selected inputs and execution conditions. 
 White box testing (also called structural testing and glass box testing) is 
testing that takes into account the internal mechanism of a system or 
component. 
 
A combination of black box and white box testing methods were used to test the real-time 
process monitoring system which was focused on the functional requirement of the 
system and was based on external characteristics of the program being tested. Validation 
used the following types of testing: 
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Intrinsic:  Features are qualified intrinsically as other features are tested. For example, 
transition function is intrinsically tested when two consecutive steps of a sequence are 
allowed to run without stopping. 
Inspection:  Features are qualified by ensuring their presence. For example, file lists and 
other documentation can be confirmed by ensuring their existence and accuracy. 
Structural testing:  Features are qualified by testing individual components as specified in 
the RD (Requirements and/or Design document). Testing will ensure that each 
requirement stated in the RD is made to execute during testing and that each requirement 
stated in the RD performs its intended function.  
Functional testing:  All the hardware used for this system is a standard hardware, which is 
subject to IQ to verify the installation and connection to components. Software category 3 
will be subjected to the validation process to ensure it meets the requirement 
specifications and design specifications. Testing will ignore that the internal mechanism 
or structure of a system or component and focuses on the outputs generated in response to 
selected inputs and execution conditions. 
In March of 1997, FDA issued final part 11 regulations that provide criteria for 
acceptance by FDA, under certain circumstances, of electronic records, electronic 
signatures, and handwritten signatures executed to electronic records as equivalent to 
paper records and handwritten signatures executed on paper [1].  
 
SIMCA is compliant with 21 CFR Part 11 (Electronic Records). "Umetrics quality 
systems for software development and validation can be audited". The audit trail is 
administrator-controlled and check-sum protected. SIMCA-4000 is OPC certified by the 
OPC Foundation. [21]. Therefore, the test cases related electronic record was performed 
to ensure the Part 11 compliance. 
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Validation Limitations and Assumptions:  
All test cases assumed that the components, systems and services of servers were 
operating as expected. The test cases also assumed that the complex calculations 
performed during the generation of multivariate models in SIMCA software were correct 
and accurate because SIMCA is COTs software. Therefore, the multivariate statistical 
calculations were not verified. Testing conducted to verify one unit operation from the 
upstream (bioreactor) and one unit operation from downstream (UF/DF) for data flow 
from historical databases to SIMCA software for MV model creation was assumed to 
work exactly the same way for every unit operation. 
 
Requirement and Design Specifications [13] 
Every computerized system and software is developed or designed based on its intended 
use. While designing the system, the developers must know the specific requirements of 
the user (a.k.a ‘User Specific Requirements’). The designed system also must meet 
certain inherent capabilities for it to function and meet the user specifications (a.k.a 
‘Functional Specific Requirements’).  In order to validate the computerized system and 
software in the cGMP environment, these URSs and FRSs were required to be tested. 
    
There can be many different kinds of requirements (e.g., design, functional, 
implementation, interface, performance, or physical). Software requirements are typically 
derived from the system requirements for those aspects of system functionality that have 
been allocated to software. Success in accurately and completely documenting software 
requirements is a crucial factor in successful validation of the resulting software. There 
are also many different kinds of written specifications (e.g., system requirements 
specification, software requirements specification, software design specification, software 
test specification, software integration specification, etc.). All of these documents 
establish “specified requirements” and are design outputs for which various forms of 
verification are necessary [13]. 
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The list of URS and FRSs were taken from the software manuals provided by the 
Umetrics and other hardware providers. They were documented in a ‘Requirement 
Specification’ and ‘Design Specification’ documents. 
 
Validation Installation Qualification, Operational Qualification and Performance 
Qualification (IQ/OQ/PQ) [13]:  
Validation is establishing documented evidence that system or software is installed as per 
the designed specifications; it operates as per the functional requirement specifications 
and performs per the user specifications [22].  
 
The real-time process monitoring system was validated per the traditional validation life 
cycle approach outlined in the Good Automation Manufacturing Practices (GAMP) 
guidance [23]. As outlined in the Figure 33 [25], IQ, OQ and PQ documents were written 
with specific test cases as listed in Table 3. The each test script in the validation protocol 
was executed to ensure that it meets the expected results.    
 
 
Figure 30, V- Lifecycle model, [Source: 25] shows that the validation approach 
utilized for software related systems. The user and function specification 
requirements are tested in the validation protocol and are tracked in the 
requirement traceability matrix.   
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Table 3, Test Cases in the Validation Protocol [13, 14, 19] 
Test 
Case # 
Description Test Intention 
1 Change Control Status 
verification (IQ) 
Prior to implementing any GMP system, the 
change control needs to be initiated 
2 Server Qualification 
verification 
Ensure that servers are configured and 
qualified to meet the functional  
3 Hardware & Software 
Installation 
verification (IQ) 
Ensure that all the hardware, software 
interfaces, database interfaces, Operating 
system, and maintenance software’s are 
installed and configured correctly,  
3 Hardware 
configuration 
verification (IQ) 
Ensure that all the hardware meet the 
processor speed, memory, graphic and driver 
settings 
4 Creation and 
installation of MV 
model and Projects 
(IQ) 
Ensure that all the MV models are created and 
saved correctly at a secured location 
5 Documentation 
verification 
Ensure that all the hardware, software related 
manual, drawings are documented and 
attached or achieved. 
6 Pre-requisite 
documentation 
Ensure that all the OQ pre-requisite 
documentation such as VP, RS and DS are 
approved prior to initiating OQ and PQ testing 
7 Standard Operating 
Procedures (SOP) 
Ensure that all the SOP’s are created for the 
operation of the GMP system. 
8 Start up and shutdown 
verification (OQ) 
Each system component (server, network 
PC’s, network devices are connected properly 
and go through flawless reboot process in case 
of power outage or routine start and shut down 
process 
9 Logical Security for 
the Operating system 
and the Software’s 
(OQ) 
Ensure that the servers and the PC’s which are 
used to operate the system have the restricted 
access so that unauthorized users cannot 
modify or delete the secured data folders/files 
or modify the recording time. 
10 Logical Security for 
the Software’s (OQ) 
Ensure that the SIMCA software has the 
restricted access so that unauthorized users 
cannot modify or create new folders/files or 
modify existing folders/files 
11 Password Security 
(OQ) 
Ensure that the users can create unique 
passwords with specific length, alpha-numeric 
combinations and allow only certain number 
of attempts. Only the application or IS 
administrator is allowed to add the users or 
reset the passwords.  
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Test 
Case # 
Description Test Intention 
12 Authority & Privilege 
levels (OQ) 
Ensure that there are different authority levels 
and the user permissions for each group so that 
each unique group can maintain different 
functions while using the software 
13 Operational Sequence 
and data flow (OQ) 
Ensure that all the required connections are 
installed and operate correctly in the intended 
sequence. 
14 Control Charts 
analysis and 
visualization of 
graphical plots 
verification(OQ)  
Ensure that the PCA and PLS MVDA control 
charts for BEM and BLM can be seen 
correctly with set confidence limits and 
average. 
15 Data Export and Data 
Management 
verification(OQ)  
Ensure that when the data is exported or saved, 
it does not alter the information. 
16 Remote Access 
verification (OQ) 
Ensure that the MVDA software can be 
accessed remotely without any flaw. 
17 Time Synchronization 
verification (OQ) 
Ensure that all the clocks are synchronized on 
the servers and the PC, so that the there is no 
error during data transfer. 
18 Backup and Restore 
verification (OQ) 
Ensure that all the data can be back-up and 
restored in case of disaster. 
19 Alert limits and Action 
limits settings 
verification (OQ) 
Ensure that the alarm limits are configured 
correctly and they show the appropriate alarm 
conditions 
20 Audit Trail 
verification (OQ) 
Ensure that the MVDA system is enabled with 
audit trail. The audit trail is human readable 
and the entries do not overwritten.  
21 End to End 
performance 
verification (PQ) 
Ensure that system meets the performance 
specification over the period of time 
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Performance Qualification (PQ) [12, 13, 22]: 
The performance verification of the real-time process monitoring system was performed 
after the IQ and OQ testing was complete. The intent of the PQ was to ensure that the 
system performed according to the expectations and was able to monitor the process in 
real-time. The test scripts were written to test one unit operation from upstream and one 
unit operation from downstream from start to end as shown below.  
 
 
 
 
Requirement Traceability Matrix (RTM) [13, 19]: 
The RTM was generated to map the functional testing of the real-time process monitoring 
system in validation documents (IQ/OQ/PQ) to the corresponding RS and DS 
specifications. This mapping helped to ensure that the requirements were met and traced 
to the appropriate qualification document(s). All requirements were verified and were 
traced to the test activity to prove that each requirement had been met.  
 
Validation Summary Report (VSR) [13, 19]: 
The VSR summarized the deliverables, validation activities, test results and deviations 
encountered during validation of the system. This document was generated at the end of 
the validation campaign to summarize a qualification conclusion that the real-time 
process monitoring system was validated and is suitable for using in the GMP 
environment.  
Summary 
The PAT enabled facility can generate data at the desired intervals. When these 
technologies are combined with Multivariate statistical methods can analyze the data to 
give meaningful information. Upon validation of the entire system can be used for real-
time process monitoring to achieve the FDA’s CPV requirements.  
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BUSINESS BENEFITS  
 
In an ideal situation and complete implementation of lifecycle approach using QbD and 
PAT tools [2] can offer several tangible and intangible benefits to the biopharmaceutical 
manufacturers. The benefits of this system include detecting raw material and equipment 
related process variability to real-time lot release as outlined below. The real-time 
process monitoring at every manufacturing step, will result in tremendous benefits to the 
manufacturers and regulatory agencies throughout the lifecycle process [10, 24].  
 
Each of the benefits listed below are associated with significant financial savings 
ultimately, cost saving and financial gains to meet the product life cycle requirements is 
the objective along with meeting the regulatory expectation. 
 
Operating Space: Leveraging scientific understanding and process knowledge helps 
process scientists to establish an operating space. The use of QbD and PAT can expedite 
technology transfer and stage 1 activities ultimately resulting in a faster scale up.  
 
Scientific Knowledge: The cost benefit is through knowledge that helps in setting the 
accurate confidence limits and operating space to an optimum level so that the process 
does not have to be modified frequently. It can save a great deal of time, money and 
resources in the long range and avoid process modifications at regular intervals.   
 
Early fault detection: There are multiple cost benefits of early fault detection. It can help 
identify the exact cause of the failure and save time during investigation. This is linked to 
timely release and patient supply. If early fault detection and the cause of failure are 
identified quickly, then the decision of corrective measures or decision to stop the batch 
can be made. This can save further processing costs and the next batch can be started 
quicker. This can also reduce the equipment downtime.   
Additional PPQ Runs: If the process is modified within, the operating space there may 
not be a need for additional PPQ runs which may reduce additional regulatory review and 
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approval. The traditional approach required change impact assessment, re-validation and 
refilling to regulatory agencies. With a QbD and PAT approach, every change made 
within the operating space is backed by scientific justification and monitored by real-time 
process monitoring. Therefore, the cost of revalidation and refilling is significantly 
reduced or eliminated.  The scientific and data driven justification for every modification 
can save time during investigations.  
 
Elimination or reduction of manual sample handling [34]: With traditional approach, 
routine samples are taken during the entire manufacturing process to ensure that the 
process is in control.  This requires a great deal of time and resources. With the 
implementation of the real-time process monitoring tool, each and every critical and key 
process parameter is monitored in real time. This can significantly reduce or eliminate the 
need for off-line sampling. This is a major cost saving benefit. 
  
Quicker investigation Time: Every process deviation requires thorough investigation and 
supporting data to justify the cause and effect. This is an extremely time consuming 
process which can delays batch release. With the real-time process monitoring tool, the 
identification of the issue and readily accessible data driven justification can reduce the 
investigation time. This can result in ensuring quicker lot release.  
 
Consistent Product Quality: With a real-time process monitoring tool, it is ensured that 
every batch is consistently meeting the quality requirement. This can help establish the 
assurance and confidence with regulatory agency and patients.  
 
Real-time Release: The real-time process monitoring tool can assist in maintaining the 
patient supply and managing the inventory. Consistent product quality with minimal 
variability and higher yield results in a higher return on investments. 
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CONCLUSION 
 
In the traditional approach, set points and operating ranges for process parameters are 
defined. The control strategy is based on the demonstration of process reproducibility and 
testing to meet the established acceptance criteria. There are certainly flaws in the 
traditional approach which needed to be improved with an enhanced approach. The 
enhanced approach is backed by risk management studies, scientific knowledge, and 
process understanding.  
The latest guidelines such as PAT framework [2], FDA’s 2011 process validation 
guideline [6] and Q11 guideline for development and manufacture of drug substances by 
FDA [7], are eliciting the same message that the innovative technologies can used in drug 
manufacturing processes.  
In this study, the use of one of the PAT tools for process monitoring showed how a state 
of control is achieved and process failures could detect batch discrepancies or sensor 
malfunctions. The study was conducted using the data from existing biologics 
manufacturing process to demonstrate the industrial application of the tool. The study 
outlined the validation of a process monitoring system to show that this tool could be 
used in the GMP environment.  Even if adapting this tool requires an initial investment, it 
can be applied easily with appropriate management support. It definitely offers 
significant enhancement to process understanding, process monitoring, and scientific 
thoroughness in decision making. It significantly enhances qualitative and quantitative 
performances and cost savings. The use of multivariate process monitoring tool provides 
an opportunity to improve control of monitoring the process real-time so that issues can 
be addressed quickly.    
There are multiple benefits of implementing PAT tools in the drug development, 
validation and manufacturing phases. In the development phase, it can provide thorough 
scientific knowledge and process understanding to achieve stage 1 – process design. In 
stage 2 – process qualification stage, it can help determine and justify the number of PPQ 
batches required for process validation. In stage 3 – the continued manufacturing stage, it 
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can help gain confidence and assurance in real-time that the batch is moving in the right 
direction. It may also reduce or eliminate the off-line testing [24].  
If the QbD and PAT tools are applied to new products then it can help establish solid    
justification for the number of batches for PPQ prior to process validation campaign.  
If the PAT tools are applied to an existing product then every batch can be monitored in 
real-time just like a process validation batch. The early fault detection can help in 
assuring that the processes are running at the optimum level within the operating space to 
give maximum efficiency, consistent quality and higher yields. This may also result in 
lower production cost and energy consumption.  
This project is expected to reduce costs by helping to better control process variability, 
improve yields, reduce waste, and ensure high-quality product consistently. The cost 
savings upon implementation of this system for the conventional manufacturing process 
or new processes can be calculated using significant number of batches, right first time, 
quality costs and other metrics. This capability not only provides financial benefit but 
ensures quality product and meets the regulatory expectation for continued/continuous 
process verification. 
The outcome of this project supports that PAT can be used for the existing or new 
manufacturing processes to achieve the FDAs lifecycle approach meeting “Continued 
Process Verification”.  
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ABSTRACT 
 
This study intends to demonstrate the benefits of a process analytical technology (PAT) 
enabling a real-time multivariate process monitoring (RT-MSPM) system to be used 
during product manufacturing. The implementation of the RT-MSPM tool shows the 
application of FDA’s 2011 Process Validation Guidance for industry to perform process 
monitoring for continuous process verification. The study was focused on the need of 
completing stage 1 - ‘Process Design’ and ‘stage 2 – ‘Process Performance Qualification 
(PPQ)’ activities for the successful implementation of stage 3 – Continued Process 
Verification (CPV)’. With sufficient scientific knowledge of process design and process 
qualification, CPV could be implemented by using PAT tools. The article focuses on the 
use of multivariate data analysis methods such as PCA and PLS to create two models: 
batch evolution and batch level models.  The data sets from historical batches for one 
upstream unit operation (bioreactor) and one downstream unit operation (UF/DF) are 
used to develop the experimental models for multivariate monitoring purposes. The study 
summarizes was conducted at a commercial biologics manufacturing facilities.    
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NEW PROCESS VALIDATION APPROACH DUE TO 2011 GUIDANCE 
 
 All drug manufacturing facilities must follow regulatory guidelines from the Food and 
Drug Administration (FDA or USFDA) such as 21 CFR Parts 210 and 211 of the cGMP 
regulations [8], 1987 process validation guidance [1] and other guidelines which are 
introduced on a regular basis. The biopharmaceutical industry has been conscientiously 
following the cGMP regulations to make consistent and reproducible commercial 
products. 
 
Yet, due to recent technological developments and innovations, the pressing need and the 
pressure challenged the drug manufacturing process. From the beginning of the century, 
FDA and other worldwide agencies introduced new guidelines such as QbD and PAT – A 
Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality 
Assurance [6], International Conference on Harmonization's Q8 for Pharmaceutical 
Development [2], Q9 for Quality Risk Management [3], Q10 for Pharmaceutical Quality 
System [4] and Q11- Development and manufacture of drug substances [5].  Regulatory 
agencies objective is to encourage the innovation in the drug manufacturing process [6].  
 
In January 2011, FDA published new guidance for industry entitled Process Validation: 
General Principles and Practices [7].  Since it is guidance from the regulatory agency, it 
is legally enforceable per the Federal Food, Drug, and Cosmetics Act. The requirements 
are called out in 21 CFR Parts 210 and 211 of the CGMP regulations, more specifically 
in Part 211.100 (a) [8].  
 
There had been a gap of exactly 25 years between FDA 1987 Guideline and the 2011 
Guidance for process validation. The 2011 Guidance is entirely consistent with the basic 
principles of process validation articulated in the 1987 Guideline.  
“Nonetheless, more than 25 years’ worth of experience and regulatory oversight, along 
with the cGMPs for the 21
st
 Century Initiative [9], prompted FDA to revisit the principles 
and concepts in an effort to update and clarify FDA’s thinking on process validation”. 
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Per this new guidance, manufacturers are urged to adopt the lifecycle approach in three 
stages [7]: 
In Stage 1, process design, the commercial process is defined based on scientific 
knowledge gained through development and scale-up activities.  
In Stage 2, process qualification, the process design is evaluated and assessed to 
determine if the process is capable of reproducible commercial manufacturing.  
In Stage 3, continued process verification, ongoing assurance is gained during routine 
production that the process remains in a state of control.  
Per 2011 guidance, FDA states that process validation is to be a lifecycle approach 
instead of being a one-time activity. The FDA’s new approach is to make ‘every 
manufacturing batch as a ‘Validated’ batch via ‘Continued Process Validation’. The 
following Figure 1 outlines the FDA’s new process validation expectation [10]. 
 
 
Figure 1: Three stages of Process Validation. FDA’s 2011 guidance requires drug 
manufacturing process to be a three stage process. Stage 1, stage 2 and stage 3. The stage 
1 activities are required for thorough scientific knowledge and process understanding is 
required to establish a robust operating space. Stage 2 represents process validation and 
stage 3 is for continued process verification.  [Source: 10] 
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DECODING THE REGULATORY EXPECTATIONS  
 
Stage 1 - Process Design: Well Characterized Process for Thorough Understanding of 
Process Parameters via ‘Risk Assessment’ 
Scientific knowledge gained during the pharmaceutical development program is critical 
for enhanced understanding of product quality and provides a basis for risk management 
and increased regulatory flexibility [11]. This stage is considered the design phase (stage 
1) of the FDA’s latest guidance. The initial scientific knowledge about the drug and its 
manufacturing process is gained prior to the validation campaign. Use of several 
laboratory scale, pilot scale and development runs for thorough understanding of process 
parameters and their critically are required. Every parameter must be evaluated utilizing 
quality risk management practices.    
 
Stage 1 – Process Design states that, “The commercial manufacturing process is defined 
during this stage based on the knowledge gained through development and scale-up 
activities [7]”. The first step to achieve this mile stone is establishing an operating space. 
 
The challenge is successfully answering a set of key question which can lead to gaining 
scientific knowledge and thorough process understanding to establish the ‘Operating 
Space’. The questions are: What are the physical, chemical and biological properties of 
the raw materials used?, What are the physical, chemical and biological properties of the 
API or drug substance?, What parameters are associated with the drug?, What are the 
operational (input) parameters?, What are the process (output) parameters, Has risk and 
criticality assessment of each parameter performed?, which once are critical, key or non-
key parameters?, What is the target set-point for each parameter?, What is the normal 
operating range of each parameter?, What is the proven operating range of each 
parameter?, What are the limits of failure?, what is the concentration of the final drug 
product?, what are the attributes being test tested to analyze the API and final drug 
product? What are the acceptance criteria for the process parameters?, How is the 
acceptance criteria established? 
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The answers to these questions helps you understand the process limits for every 
parameter you need to establish the design space as shown in Figure 2 [12]. ICH 
guidance Q8, defines it as “the multidimensional combination and interaction of input 
variables and process parameters provides the assurance of quality [2]”. 
 
 
Figure 2: Design Space [Source: 12] 
 
The scientific knowledge of operating space provides the understanding of variability in 
raw materials, the relationship between a process and product’s critical quality attributes 
(CQAs), and the association between CQAs and product’s clinical properties. This 
through understanding can help “Control the variation in a manner commensurate with 
risk it represents to the process and product [7]”. The scientific knowledge of drug and 
process parameters can be achieved by conducting a design of experiments (DOE) a.k.a 
characterization studies. The high degree of scientific knowledge and assurance in the 
performance of the manufacturing process is obtained from objective information and 
data from laboratory, pilot, and/or commercial scale studies [7].  The results obtained 
from these studies define the operating space. DOE studies can help develop process 
knowledge by revealing relationships, including multivariate interactions between the 
variable inputs (e.g., component characteristics or process parameters) and resulting 
outputs (e.g., in-process material, intermediates, or final product) [13]. 
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Performing the Risk Assessment [13]: 
 
The most import task is performing a risk assessment of the operational and process 
parameters identified during characterization studies of the DOE. Per the 2011 guideline, 
‘All the parameters should be evaluated in terms of their roles in the process and impact 
on the product or in-process material [7].  A team of representatives from manufacturing, 
process development, quality assurance and validation are required to perform the 
assessment. A typical quality risk management model outlined in Figure 3 [3] is 
commonly used as described in the ICH Q9, Quality Risk management [4]. Each and 
every parameter identified during a characterization study is evaluated to find out what 
might go wrong? The likelihood of it going wrong and the consequences of it are 
discussed during the risk assessment.  Based on the evaluation of the risk model, a score 
is assigned in three different categories such as low, medium and high. The risk 
parameters are weighted against the likelihood of occurrence, probability of detection, 
and severity of consequences. All three scores are multiplied to obtain a risk priority 
number (RPN) as shown in Figure 3 [3]. A decision is made to identify the parameter as 
critical, key or non-key to merit process characterization. 2011 guidance expects, ‘a 
higher degree of control for the parameters that pose higher risk [7]. The results are 
documented as characterization reports to establish the operating space.  
 
Figure 3: Risk Assessment Tool. During the risk assessment process, each and 
every process parameter is evaluated using a risk assessment tool [Source: 3] 
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Figure 4: Risk assessment grid. The risk assessment grid is used to assign the 
RPN number for each and every process parameter associated with process which 
is evaluated and scored based on the risk likelihood and, risk severity. [Source: 
14]  
 
The operational ranges for the operational parameters and acceptance criteria for the 
process parameters in the design space are the basis for process validation protocols to 
validate the process [15]. The scientific knowledge and information gathered must be 
documented, and approved in accordance with the established procedure so that it can be 
used in the stage of lifecycle [7].   
 
Stage 2: Process Performance Qualification (PPQ) 
 
The goal of validating any manufacturing process is to establish scientific evidence that 
the process is reproducible and will consistently deliver quality products. The sufficient 
scientific knowledge and assurance gained during stage 1 via characterization studies, 
sets the stage for stage - 2 process qualifications. How do the characterization studies 
help in process performance qualification (PPQ)? FDA’s 2011 guidance outlined that the 
manufacturers should [7] understand the sources of variation, detect the presence and 
degree of variation, understand the impact of variation on the process and ultimately on 
product attributes, and control the variation in a manner commensurate with the risk it 
represents to the process and product.  
 100 
 
 
The scientific evidence gathered during characterization provides the appropriate level of 
assurance that the manufacturing system has been designed to consistently deliver a 
quality product to the market. The specific information obtained from the operating space 
such as the critical/key parameters and, control strategy to set the normal operating 
ranges (NOR) and proven acceptable ranges (PAR).  This information derives the 
scientific justification for the parameters selection and to calculate and establish the 
control limits which serves as an input for PPQ protocol. 
 
This phase involves evaluating the facility and equipment for its fitness for use. Utility 
systems and equipment are verified to be built and installed properly, and operators ensure 
that they operate within the intended and anticipated operating ranges. During the PPQ 
stage of process validation, the process design is evaluated to determine if it is capable of 
reproducible commercial manufacture of products [7]. The decision to distribute the 
product to the market is determined by the successful completion of the PPQ. The 
successful completion of the PPQ demonstrates that the commercial manufacturing 
process performs as expected. 
 
Number of PPQ Batches: 
 
One of the most important discussion and interpretation of FDA’s 2011 guideline is about 
the number of batches. Until the new guidance came along, the process validation was 
done by performing a three-batch requirement. “...it was widely accepted throughout 
industry, and, indeed, implied or stated in some FDA guidance documents, that process 
validation was a static, three-batch demonstration event. [16]”. The EU GMP Annex 15 
states that “It is generally considered acceptable that three consecutive batches/runs within 
the finally agreed parameters would constitute a validation of the process” [17].  The 2011 
guidance does not mention anywhere about the number of PPQ runs required for 
successful completion PPQ stage. The decision about number of PPQ batches it open for 
interpretation. One can interpret that ‘process validation as a continuous process of 
collection and evaluation of data, rather than as a three-batch static event” [10]. 
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The number of batches is not an acceptance criterion; however, the results of the data 
obtained from the batches are the acceptance criteria. The new definition of validation 
caused one industry member to state at the workshop that for the past 30 years, industry 
has been told that process validation is a documentation exercise. FDA expects industry to 
consider process validation as a scientific endeavor. That is quite a shift and 30-year 
habits are hard to break [10, 18, 19]. 
 
The existing products which are already in the market may have already crossed this 
hurdle by making three process validation (PV) batches, which got the approval of FDA 
for commercial manufacturing. The 2011 guidance is also applicable to these products. 
The FDA directive for the manufacturers of these products is to follow the life cycle 
approach. The legacy product manufacturers benefit from the knowledge they have 
already gained about the manufacturing process and the product over course of the 
commercial manufacturing. Use of PAT tools for these manufacturing processes can 
really enhance their process monitoring capabilities to achieve the stage 3 – continued 
process verification.  
 
At the same time, new products and new manufacturing processes have the benefit of 
following the QbD and PAT principle right from the beginning to gain process 
understanding during stage 1 so that they can scientifically justify the number of batches 
required for PPQ. The manufacturers must make deliberate, rational decisions about 
whether their specific processes are validated and their products ready for commercial 
release. A manufacturing process that uses PAT may warrant a different PPQ approach. 
PAT processes are designed to measure in real time the attributes of an in-process 
material and then adjust the process in a timely control loop so the process maintains the 
desired quality of the output material [7]. 
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Justification for selecting number of batches for PPQ: 
The PPQ validation strategy can be used to scientifically justify the required number of 
batches selected for PPQ. The knowledge gained from previous molecules and during the 
process design stage through development, scale-up activities and engineering runs can 
be used to demonstrate that the current process is well characterized. A thorough process 
understanding has been developed by virtue of a comprehensive set of pilot and 
robustness studies. Operating parameter and performance parameter classifications and 
ranges have been determined, and a strategy for overall process control has been 
established. The operating and performance parameter classifications and ranges have 
been developed based on the studies performed as part of Stage 1 Process Design and 
documented in the characterization report. A manufacturing process at commercial scale 
is established based on this process knowledge. This information can be used to justify 
the required number of PPQ runs. By establishing the sufficient data, scientific 
justification can be provided to prove that one, two or five process validation runs are 
sufficient instead of three process validation runs per the traditional approach. 
 
Sampling during PPQ batches: 
 
The 2011 guidance also emphasized on the sampling plan, sampling points, number of 
samples, frequency of sampling for each unit operation and using a statistical approach 
for PPQ samples.  The number of samples should be adequate to provide sufficient 
statistical confidence of quality both within a batch and between batches [7]. The use of a 
statistical tool and the approach is not specified but the manufacturers are expected to 
choose a suitable statistical tool. Homogeneity within a batch and consistency between 
batches are goals of process validation activities. The expectation is to use the heightened 
sampling and monitoring period to gain the confidence and assurance for the high risk 
parameters.   
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Stage 3 – Continued Process Verification (CPV):  
The goal of the third validation stage is continual assurance that the process remains in a 
state of control (validated state) during commercial manufacture. A system needs to be in 
place for detecting unplanned departure from the process as designed during stage 1 and 
stage 2 [7]. Ideally, this stage should be treated as extension to stage 1 and stage 2 
because all the scientific knowledge of operating space and its verification is done during 
process validation phases. But, this is still creating confusion because it is a new concept 
and the expectations stated in the 2011 guidance are vague.  
The new guidance outlines that upon regulatory filing and receiving the approval for 
commercial manufacturing, the manufacturers maintain the same state of control as it was 
shown during PPQ runs to ensure that each batch is a process validation batch. When 
implementing stage 3, manufacturers should consider the semantic difference between 
the terms “continued” and “continuous”. The 2011 Guidance deliberately speaks to 
continued process verification, which some organizations have misinterpreted to mean 
continuous, with mandatory enablement via PAT. The expectation is decidedly not that 
in-process or release testing required under the cGMP regulations be replaced by PAT 
approaches. Rather, the expectation is for ongoing, (i.e., inter and intra-batch, monitoring, 
and review) [18]. 
The 2011 guidance has been rolled out for two and half years. Most of the manufacturers 
are still in the process of digesting this concept. By taking the hints from the 2011 
guidance, various ideas are being explored. Most of the manufacturers are in the process 
of modifying their procedures to adapt the CPV philosophy so that they can slowly but 
steadily join the band wagon. Some manufacturers are ahead in the game because they 
were early adaptors of QbD and PAT principles. Here are some of the examples 
discovered from the workshops and seminars on CPV interpretation and adaption: 
Current practices for the implementation of CPV [20]: 
Sampling during CPV: Instead of monitoring PPQ level sampling, only a few appropriate 
parameters are selected for the stage 3 sampling plan. The data is collected from these 
parameters until sufficient information is available to generate sufficient variability 
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estimates by review of historical data trends. Standard operating procedures (SOP) are 
put in place to define additional monitoring and the heightened sampling and monitoring 
period [21], list of additional parameters monitored, and statistical methods to measure 
Process Capability and Product Trends review [7]. 
Review of Supplier Audit: The incoming materials are ensured to be in a state of control. 
This can be demonstrated by [19] supplier audits and by verifying documents such as 
supplier quality agreements, certificates of analysis and raw material testing results. 
MMP (Master Monitoring Plan):  The drug manufacturers are planning to monitor the 
critical and key process parameters using pre-defined master monitoring plans for the 
products prior to commercial manufacturing so that the data and the data trends can be 
routinely monitored. Once the MMP is put in place, any change to the operating 
conditions (ranges and set-point), process controls post filling and regulatory 
inspectional commitments can be reflected in the MMP.  In order to have a robust MMP, 
preliminary process control limits and centerlines (if applicable) must be established for 
all in process control (IPC) parameters and critical and key post-filling parameters being 
monitored at or about lot 15. The statistical process control limits and centerlines (if 
applicable) must be established for all IPC parameters and critical and key post-filling 
parameters being monitored at or about lot 30. 
 
Monitoring Quality Systems: There are other periodic review quality systems are also 
being used to monitor the achieve CPV such as periodic review of post approval change 
control process [7], periodic review of non-conformances and defect reporting systems, 
verification of Root Causes and CAPA process, periodic review of validated equipment, 
systems and utilities at regular intervals, periodic review of monitoring for CIP and SIP 
cycles, periodic review, monthly and annual review of equipment and facility 
qualification [7], incorporating appropriate detection, control and mitigation strategies, 
collecting regular feedback from the process operators and quality staff on the process 
performance and maintaining and reviewing the product complaints data. 
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Statistical Evaluation and Analysis of Process Data [7, 21] 
The drug manufacturers are following the FDA’s suggestion of using statistics in the 
evaluation of data trends for analyzing the data. In order to achieve this, all IPC 
parameters and critical and key post filling parameters must be monitored starting from 
the first lot scheduled for commercial release. The product specific control limits must 
be established using generally accepted statistical process control practices with upper 
and/or lower control limits computed nominally at three standard deviation units from 
the mean for normally distributed data. The use of Nelson rules for supporting the 
making the statistical decisions is followed by many drug makers. As outlined in Nelson 
rules [22], all parameter results from each production lot must be examined across lots 
for statistically abnormal behavior. This approach shall include using the following 
Nelson (NEL) run rules for normally distributed parameters: 
 NEL 1: One point beyond a control limit 
 NEL 2: Nine points in a row on one side of the centerline 
 NEL 3: Six points in a row steadily increasing or decreasing 
 NEL 4: Fourteen points in a row alternating up and down 
 
Use of PAT Tools: Lastly, due to the technological developments, many new process 
capabilities are available for manufacturers. They can install the on-line, at-line and in-
line sensors to monitor critical and key process parameters in real-time. Installation of an 
electronic data collection system is a new trend in the industry, which stores batch 
historical batch data so that this data can easily accessed to analyze the trends between 
batches and within the batches.  The use of multivariate statistical analysis methods for 
real time process monitoring [23] is also a growing trend. 
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INDUSTRIAL APPLICATION OF PAT TOOL TO ACHIEVE CPV 
 
As discussed in the previous section, the manufactures are in the process of implementing 
various tools to include CPV into their manufacturing processes to meet the FDA’s 2011 
guidance. The use of real-time multivariate statistical process monitoring system is 
utilized here to show the how CPV can be achieved.   
Material 
SIMCA Software v13.0.3 [8]: The SIMCA software version 13.0.3 is utilized for the 
creation of statistical MV models.  This software is developed by Umetrics.  
This software is used to create design of experiments and multivariate data analysis. This 
tool transforms data into information, which can be seen in the form of colorful graphical 
control charts to enable the process analyst to make the correct decisions and take the 
appropriate actions in real-time.  
 
Historical data from the good batches (batches which have minimum deviations) are used 
from one of the well-known commercial biological manufacturing process. The data is 
extracted from the historical databases by making configurations, tags, scan rates, and 
compression settings to the source system. This data is pre-treated and organized in 
appropriate format prior to importing it into the SIMCA software for the creation of 
multivariate models.  
 
Methods  
 
Two popular and commonly used Multivariate Data Analysis (MVDA) Methods are 
principal components analysis (PCA) and partial least squares (PLS), which are used to 
show the use of the PAT tool described in the QbD, and PAT framework. [PAT 
Framework, QbD [2, 11, 24]. 
The commercial biological manufacturing process is enabled with various modern 
process analyzers and is equipped with a distributed control system to collect the process 
data. The real-time multivariate statistical process monitoring system is linked to the 
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process databases obtain the process data.  Various modifications were made to the 
existing databases for the collection of data from the unit operations. The study is focused 
one upstream unit operation (i.e. bioreactor) and one downstream unit operation (i.e. 
UF/DF).    
The propriety data were modified and normalized as necessary prior to using it for the 
creation of the multivariate (MV) model in SIMCA application.    
The goal is to demonstrate that the following PAT tools can be utilized to ensure 
continued process verification is met as outlined in FDA’s 2011 process validation 
guidelines [7]: 
I. Multivariate data acquisition and analysis  
II. Continuous improvement and knowledge management tools  
 
Most of the existing manufacturing processes for biologics product at scale are not 
designed to inherently enable the real-time process monitoring. The real-time process 
monitoring (PAT software tools) and QbD principles are required for monitoring a 
biologics manufacturing process in “Real-Time”.  
The bioreactor and UF/DF unit operations were monitored against the input parameters 
listed in table 1 and table 2. These unit operations were connected to the distributed 
control system (DCS) to collect the process data [11]. The process database was 
connected to DCS, which saved the historical and current batch data continuously 
generated from the ongoing batches. The continuous plant data historian was configured 
with the correct tags. The cell viability and viable cell density data were also collected 
from off-line measurements to check the process performance at twenty-four hour 
intervals during the course of the unit operation. The configuration of trigger tags, timers 
and batch tags were made as required to get all the relevant batch and continuous process 
data from the historical databases. 
 
The on-line data was collected at fifteen minute intervals for the bioreactor unit operation 
and at 10 second intervals for UF/DF unit operation. The data from fifteen batches were 
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used for the creation of MV model and control charts for the real time statistical process 
monitoring. The historical batches which had lowest number of deviations and alarm 
conditions were selected as an input for the MV model creation. The goal for this 
selection criterion was to create a reference MV model. The MV created the average and 
± 3 standard deviation for the confidence limits for the control charts. Two new batches 
were selected for the analysis to find out if they were good or bad batches. One batch of 
the two new batches data was deliberately modified by making known changes to certain 
variables for testing purposes.  This study was used to prove if the real-time multivariate 
statistical process monitoring system can achieve: 
 
1. Real time process monitoring  
2. Fault detection due to process failure or sensor malfunction  
3. Root cause analysis and process control   
 
MV Model Creation for Bioreactor and UF/DF unit Operation  
 
Bioreactor: The dataset contains data for N=17 batches. Out of these, fifteen batches were 
selected for the creation of MV model. The batch selection criteria were to have little 
variability among the batches used for the bioreactor cell culture process. The main 
objective of the study was to create a MV model so that it could be used as a reference to 
monitor new batches as they evolve and identify good batches from the bad batches. 
Fourteen variables (J=14) were monitored and the data was collected at every fifteen 
minute interval, giving a total of ~ K = 279 time points per batch. The total duration of 
the unit operation was 68 hours, and 30 minutes. The bioreactor unit operation is assumed 
a single phase process. 
 
MV for UF/DF: The dataset contains data for N=17 batches. Out of these, fifteen batches 
were selected for the creation of the MV model. The batch selection criteria were to have 
a little variability among the batches used for the UF/DF process. The main objective of 
the study was to create a MV model so that it could be used as a reference to monitor new 
batches as they evolve and identify good batches from the bad batches. Nineteen 
variables (J=19) were monitored and the data was collected at ten second interval, giving 
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a total of ~ K = 800 time points per batch. The total duration of the unit operation was 2 
hours: 31 minutes: 10 seconds. UF/DF unit operation has three phases such as 
concentration, diafiltration and recovery. 
The data are scaled to UV variance and unfolded by the SIMCA software prior to using 
for the model creation [24].  
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Table 1: Bioreactor Variables Monitored 
Variable 
Name 
Unit of 
Measure 
Variable 
Type 
Variable  
Class 
Variable Use 
Dissolved O2 % Operating Input 
Dissolved oxygen is monitored 
as a measure of cell culture 
performance 
Culture pH pH units Operating Input 
pH affects final viable cell 
density 
Air flow sLPM Operating Input 
Air flow is monitored as a 
measure of cell culture 
performance 
O2 flow sLPM Operating Input 
O2 flow is monitored as a 
measure of cell culture 
performance 
CO2 flow sLPM Operating Input 
CO2 flow is monitored as a 
measure of cell culture 
performance 
Bioreactor 
level 
L Operating Input 
Bioreactor level is monitored to 
maintain consistent volume 
Agitation RPM Operating Input 
Agitation maintains a 
homogenous solution and 
oxygen transfer to the cells 
Vessel 
pressure 
psig Operating Input 
Pressure influences mass 
transfer and mitigates 
contamination 
Temperature °C Operating Input 
Temperature (controlling 
probe) excursions  can impact 
final viable cell density and 
viability 
Culture 
duration 
days Operating Input 
Culture duration affects final 
viable cell density and is the 
maturity variable 
Temperature 
probe 
difference (A-
B) 
°C Operating Input 
Temperature probe difference 
(A-B) is monitored to detect 
equipment drift or malfunction 
VCD 
10
6
 
cells/mL 
Performance Output 
VCD is monitored as a measure 
of cell culture performance. 
Viability % Performance Output 
Viability is monitored as a 
measure of cell culture 
performance. 
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Table 2: UF/DF Variables Monitored 
Variable Name 
Unit of 
Measure 
Variable 
Type 
Variable  
Class 
Variable Use 
Feed pressure psig Operating Input 
Feed pressure is monitored to 
detect excursions in pressure 
Retentate pressure psig Operating Input 
Retentate pressure is 
monitored to detect 
excursions in pressure 
Permeate pressure psig Operating Input 
Permeate pressure is 
monitored to detect 
excursions in pressure 
Transmembrane 
pressure (TMP) 
psig Operating Input 
TMP is monitored to detect 
any excursions in pressure 
Feed flow LPM Operating Input 
Feed flow is monitored to 
detect any excursions in flow 
rate 
Retentate flow LPM Operating Input 
Retentate flow is monitored 
to detect any excursions in 
flow rate 
Permeate flow LPM Operating Input 
Permeate flow  is monitored 
to detect any excursions in 
flow rate 
Feed Retentate DP  psig Operating Input 
Feed retentate pressure is 
monitored to detect 
differential pressure 
Permeate flux L/hr/m2 Operating Input 
Permeate flux (permeate flow 
rate normalized by membrane 
area) is monitored to detect 
excursions in flow rate 
Permeate UV AU Operating Input 
Permeate UV is monitored to 
detect product loss during 
UF/DF II 
Permeate 
conductivity 
mS/cm Operating Input 
Permeate conductivity is 
monitored to ensure product 
conductivity targets 
Concentration 
factor 
N/A Operating Input 
Concentration factor is 
monitored to ensure 
concentration targets are met 
Diafiltration 
Factor 
L Operating Input 
A minimum number of 
diavolumes are required to 
meet pH and conductivity 
specifications for the UF/DF 
II Pool 
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Variable Name 
Unit of 
Measure 
Variable 
Type 
Variable  
Class 
Variable Use 
Feed flow process 
totalizer 
L Operating Input 
Feed flow totalizer is 
monitored to ensure 
concentration and 
diafiltration targets are met 
Permeate flow 
process totalizer 
L Operating Input 
Permeate flow totalizer is 
monitored to detect any 
excursions in the total 
permeate volume 
Retentate flow 
process totalizer 
L Operating Input 
Retentate flow totalizer is 
monitored to ensure 
concentration and 
diafiltration targets are met 
and is the maturity variable 
Permeate control 
valve 
% Operating Input 
Permeate control valve is 
monitored as a controller 
output 
Retentate control 
valve 
% Operating Input 
Retentate control valve is 
monitored as a controller 
output 
Step yield % Performance Output 
Step yield is monitored as a 
measure of UF/DF 
performance. 
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The MV model created for bioreactor unit operation using fifteen good batches is shown 
in Figure 5a and Figure 5b by a score plot and a batch contribution plot. The MV model 
created a default 95% confidence limit using F distribution, which is shown by an 
ecllipse in Figure 5a.  In Figure 5b, the batch contribution plot shows a ±3 standard 
deviation and averages using the data from the reference batches. The ±3 standard 
deviation and averages are shown in red and green. Figure 5a and Figure 5b plots show 
that all batches are aligned properly and ending in a similar fashion within the confidence 
limits.   
 
 
 
Figure 5a: The Score Plot (BEM) for bioreactor. The score plot was created for 
the bioreactor using the scores of first two principal components. The score plot 
shows that all batches are aligned properly and fitting the 95% confidence limit 
ecllipse. 
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Figure 5b: The PC 1 Score Batch Plot for bioreactor. The batch score plot for the 
bioreactor using the scores of the first principal components on the vertical axis 
and the elapsed time on the horizontal axis. The score plot shows that all  batches 
are starting and ending within a similar fashion within ±3 standard deviation 
confidence limit. 
 
UF/DF unit operation has three different phases. Therefore, SIMCA created three 
separate batch evolution models for each phase. The UF/DF MV model for the 
concentration phase is shown in Figure 6a and 6b. The model is created using fifteen 
good batches and is depicted by a score plots and a batch contribution plot. The MV 
model created a default 95% confidence limit using F distribution which, is shown by an 
ecllipse in the Figure 5a.  In Figure 5b, the batch contribution plot shows a ±3 standard 
deviation and averages using the data from the reference batches. The ±3 standard 
deviation and averages are shown in red and green. Figure 5a and Figure 5b plots show 
that all batches are aligned properly and ending in a similar fashion within the confidence 
limits.   
 
 
 115 
 
 
 
Figure 6a: The Score Plot (BEM) for UF/DF. The score plot created for UF/DF 
using the scores of the first two principal components. The score plot shows that 
all batches are aligned properly and fitting the 95% confidence limit ecllipse. 
 
 
 
 
Figure 6b: The PC 1 Score Batch Plot for UF/DF. The batch score plot for UD/DF 
using the scores of the first principal components on the vertical axis and the 
elapsed time on the horizontal axis. The score plot shows that all batches are 
starting and ending within a similar fashion within ±3 standard deviation 
confidence limit. 
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Use of MV Model for real time process monitoring and fault detection  
 
In this section, we can see how these models can be used to monitor the new batches as 
they evolve. If the new batch is a good batch then it is expected to evolve with in the 
confidence limits. This can be seen on the control charts. At the same time, if for any 
reason, there is a deviation then the cause and source of the deviation can be tracked 
using control charts. Introduction of this tool within the cGMP manufacturing facility 
which is equipped with the on-line data collection technologies can monitor every new 
batch in real time and provide an opportunity for continuous improvement and scientific 
knowledge management to meet the FDA’s stage three life cycle approach.    
In order to test the real-time process monitoring system to ensure the continued process 
verification, two new batches were selected for both the bioreactor and UF/DF unit 
operations each. One of the two new batches was a good batch and the second new batch 
was deliberately modified by making deliberate changes to a few variables to see if they 
can be detected by the real-time process monitoring system.  
In this case study 1, a new batch (batch# 1016) was projected on MV model created for 
the bioreactor process using fifteen good batches to see if this batch was running in the 
state of control. The batch score plot and the individual batch plot in Figure 7 showed 
that the batch# 1016 (shown in red) was well within the 95% control limit. The batch 
contribution plot shows that batch# 1016 was moving within ± 3 standard deviations 
shown in red and around the average (shown in green). 
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Figure 7: The batch score plot for the bioreactor batch# 1016. The plot shows that 
it was within the 95% confidence interval. The individual batch plot shows that 
the batch 1016 moved within ±3 standard deviation confidence limit. 
In this case study 2, a new batch (batch# 1017) was projected on the MV model created 
for the bioreactor process using fifteen good batches to see if this batch was running in 
the state of control. The batch score plot and the individual batch plot in Figure 8 showed 
that batch# 1017 (shown in red) was outside of the 95% control limit. The batch 
contribution plot showed that batch# 1017 is outside of ±3 standard deviations at several 
time points. This graphical presentation of new batch in real time reveals that the batch 
was not a good batch and the cause of deviation to be addressed immediately.  
 
 
Figure 8: The batch score plot for the bioreactor batch# 1017. The plot shows that 
it was outside of the 95% confidence interval and the individual batch plot shows 
that the batch# 1017 moved outside of ±3 standard deviation confidence limit at 
several time points. 
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In order to find out the cause for the batch deviation, the contribution plot for each 
variable was evaluated. It revealed that the pH and the temperature sensors were 
malfunctioning. Figure 9 shows the pH and temperature batch plots with the specific time 
points where the batch was out of the confidence limit. 
 
 
Figure 9: The Variable Batch Plots for pH and Temperature. The plot shows the 
exact time points where the batch was outside of ±3 standard deviation confidence 
limit.  
In this case study 3, a new batch# 116 was projected on MV model created for UF/DF 
using fifteen good batches to see if this batch was running in the state of control. A batch 
score plot and a batch contribution plot in Figure 10 shows that the batch# 116 (shown in 
red) was well within the 95% control limit. The batch contribution plot shows that batch# 
116 was moving within ± 3 standard deviations (shown in red) and around the average 
(shown in green). 
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Figure 10: The Batch Score Plot for the UF/DF batch# 116. The plot shows that it 
was within the 95% confidence interval and the individual batch plot shows that 
the batch# 116 was evolving within ±3 standard deviation confidence limit.  
 
In this example 4, a new batch# 117 was projected on the MV model created for the 
UF/DF using fifteen good batches to see if this batch was running in the state of control. 
The batch contribution plot in Figure 11 shows that batch# 117 was outside of ±3 
standard deviations at several time points. This graphical presentation of new batch in 
real-time revealed that the batch was not a good batch and the cause of deviation to be 
addressed immediately. 
 
Figure 11: The Batch Score Plot for the UF/DF batch# 117. The plot shows that it 
was going outside of ± 3 standard deviation at several places. 
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In order to find out the cause for the batch deviation, the batch plot for each variable was 
evaluated. It revealed that the feed pressure and feed flow sensors were malfunctioning. 
Figure 12 shows the feed pressure and feed flow contribution plots with specific time 
points of where the batch was outside of the confidence limit. 
 
 
Figure 12: The Variable Batch Plot for Feed Pressure and Feed Flow for batch# 
117. The plot shows the time of when the feed pressure and feed flow were 
outside of ± 3 standard deviation confidence limits.  
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Benefits of MVDA PAT Tool   
 
The above examples show that the use of a multivariate process monitoring tool enables 
the real-time process monitoring for the timely fault detection and analysis. The tool also 
helps in detecting the root cause.  
 
In an ideal situation complete implementation of a lifecycle approach using QbD and 
PAT tools, the raw material and equipment related process variability could be identified 
early on leading to thorough process understanding and effective process control of a 
particular process. The process scientist can take scientific, risk based decisions to 
justify the changes made within the operating space. This will result into tremendous 
benefits to the manufacturers and to the regulatory agencies during approval process as 
listed below:  
 
Each of the following benefits can be transformed into financial benefit. There are a lot 
of cost savings associated with each benefit. Ultimately, cost savings in the long range to 
meet the product and prize demand is the ultimate objective along with meeting the 
regulatory expectation. 
 
Benefits [6, 13, 25]: 
1. Thorough understanding of the process makes it easy to establish an operating 
space.  
2. Provides the scientific knowledge and classification of each and every input 
and output parameters 
3. Early fault detection  
4. Process changes within operating space may not require additional PPQ runs 
which may reduce the frequent regulatory review and approval  
5. Scientific and data driven justification for every future modification will save 
time during investigations 
6. Consistent and better quality product; a more robust manufacturing process 
7. Consistent product quality with minimal variability and higher yield  
8. Real time release 
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CONCLUSION 
 
The latest Q11 [5] guideline, along with a new Process Validation guidance by FDA for 
process validation [7] about Continued Process Verification are eliciting the same 
message that “Process validation should not be viewed as a one-off event. A lifecycle 
approach should be applied linking product and process development, validation of the 
commercial manufacturing process and maintenance of the process in a state of control 
during routine commercial production”.  
With this, the regulatory agencies are encouraging the manufacturers to implement the 
QbD and PAT. In the traditional approach, set points and operating ranges for process 
parameters are defined and the control strategy based on the demonstration of process 
reproducibility and testing to meet the established acceptance criteria. There are certainly 
flaws in the traditional approach which can be improved with an enhanced approach. The 
enhanced approach is backed by risk management studies, scientific knowledge, and 
process understanding. The process knowledge and understanding gained during the 
process design and process qualification stages can be utilized to develop appropriate 
control strategies which are applicable over the lifecycle of the product. 
The RT-MSPM system used in the study can be applied to any legacy manufacturing 
process. Even if it requires investment of resources and time, it can be applied easily with 
appropriate management support. It can definitely offer a significant enhancement to 
process understanding, process monitoring, scientific thoroughness in decision making 
qualitative and quantitative performances and cost savings. The use of MVDA tool 
provides an opportunity to have better control on monitoring the process real-time so that 
issues can be identified and addressed quickly.  
There are multiple benefits of implementing a PAT during the drug development phase, 
and manufacturing phase. In the development phase, it can provide process 
understanding. In manufacturing phase, it can help gain the real-time monitoring and 
assurance that the batch is moving in a right direction.  It can also eliminate off-line 
testing and minimize batches that are out of specification [25]. 
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If QbD and PAT are applied to new products, a sufficient number of bench scale, 
development runs and engineering runs are performed to obtain sufficient data then the 
justification for a number of batches required for PPQ can be easily made prior to process 
validation campaign.  
If the MVDA tool is applied to an existing product, then every batch can be monitored in 
real-time similar to a process validation batch. The early fault detection and any deviation 
from the targeted range can be detected in real-time. These capabilities not only provide 
financial benefit but also meet the regulatory expectation for continued/continuous 
process verification. 
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